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OPTIMIZATION OF GRADIENT CHROMATOFOCUSING FOR THE
PROTEIN SEPARATION AND LC-MS/MS DETERMINATION OF NGP1-01 IN
MOUSE SERUM, BRAIN, AND RETINA

HARINI JOGIRAJU

ABSTRACT

Gradient chromatofocusing (GCF) is a chromatographic technique
developed by our laboratory that generates linear pH gradients using weak anionexchange HPLC with inexpensive low-molecular buffer components. This method shows
significant advantages over conventional chromatofocusing and salt gradient ionexchange chromatography in protein separation on DEAE column. In GCF an elution
buffer (consisting of multiple acidic buffers with evenly spaced pKa values) is mixed in
successively greater proportions with application buffer (composed of multiple basic
buffers with evenly spaced pkas), to generate a smooth linear pH gradient. GCF has the
advantage of giving an estimate of the protein pI and being able to be directly interfaced
to a mass spectrometer when volatile buffers are used.

Although GCF yields considerable success in protein separation, extensive study
has not been done yet. Further characterization and method optimization studies in GCF
are done in the present work. Chapter 1 describes the characteristics of the conventional
ion-exchange chromatography, chromatofocusing, and gradient chromatofocusing for
protein separation.

iv

In the second chapter, a new method with smooth linear pH- gradients on self
packed DEAE anion-exchange column was developed by introducing “bridging” buffers
between application and elution buffers. This was employed for the chromatographic
separation of a mixture of conalbumin, rat albumin, and β-lactoglobulin which resulted
with good resolutions.
In the third chapter, the effect of the number of buffer components on protein
separation in high-performance gradient chromatofocusing ion-exchange using linear pHgradients was studied. The results showed that the number of buffer components has
significant effect on protein separation. Results showed the increased resolutions and
decreased peak widths at half height were obtained with increased number of buffer
components. This optimized GCF technique was applied to the separation of prolactin
isoforms by a PEI weak anion exchange column.

In chapter four, the development and validation according to FDA guidelines of a
sensitive quantitative LC-MS/MS method for the determination of a neuroprotective
compound, NGP1-01, in mouse serum is described. The developed method was applied
to preliminary pharmacokinetic studies to quantify NGP1-01 in limited number of dosed
mouse serum samples to show the suitability for undertaking full NGP1-01
pharmacokinetic studies.

v
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CHAPTER I

OPTIMIZATION OF GRADIENT CHROMATOFOCUSING FOR THE
PROTEIN SEPARATION

1.1. Background and significance

Proteins are important large biological molecules that play critical roles in almost
all biological processes. They are building blocks for living cells and serve as functional,
structural and regulatory agents of the body’s processes. Types of proteins include
antibodies, enzymes, hormones, messengers, structural components, transporters, and
others. There are about 30,000 proteins in human bodies translated from the estimated
30,000 human genes. These proteins undergo post-translational modifications. So it is
estimated that the human body may contain over two million proteins, coded for by only
20,000 – 25000. With this enormous diversity of proteins, separation techniques are
essential in the analytical determination of a particular problem. To perform in
vitro analysis, a protein must be purified away from other cellular components [1, 2].

1

High performance liquid chromatography (HPLC) is emerging as an essential
technology in the purification and separation of proteins due to its high efficiency and
high resolution capabilities. Protein HPLC can be categorized based on the separation
mechanism into ion-exchange, reversed phase, size exclusion, hydrophobic interaction,
affinity, and metal interactions [3-5]. Due to its non-denaturing characteristics and charge
based separation, high resolving power, versatility, high protein binding capacity, and
ease of operation, ion-exchange HPLC is one of the important and most utilized
techniques in protein separation and purification [6, 7].

1.2.

Ion-exchange chromatography

1.2.1. Overview

Ion-exchange chromatography is the most widely used HPLC technique that separates
and purifies proteins based on their overall charge either salt-gradient or pH-gradient
elution [8]. The principle of ion-exchange chromatography in the salt gradient elution is
based on the competitive interaction between sample molecules and salt ions for the
charged functional groups on the stationary phase [9]. Ion-exchange chromatography
retains the molecules by the reversible interaction of electrostatic charges of the solute
molecule functional groups with an opposite charge of the ion-exchanger functional
groups [10]. To maintain neutrality, the charges on both the analytes of interest and the
ion exchanger are associated with ions of opposite charge, termed counter ions [11].

2

The ion-exchange process can be described [12] by taking into account an anionexchange resin, where R-X+ is fixed charge group and A- is a counter ion or the analyte
ion for anion- exchanger and B- is a different counter ion present in the mobile phase
introduced onto the ion-exchanger which displaces the counter ion or the analyte ion of
ion-exchanger .

Equilibrium is established between two ions A- and B- as follows:
R-X+ A- + B- ↔ R‒ X+ B- + A-

In ion-exchange HPLC, the ion-exchangers consist of three parts: a stable base support,
fixed charge groups which are attached to base support, and counter ions. The base
support for HPLC should meet the following requirements: particle size should be small
and uniform, must provide high physical strength to resist the high pressure, chemically
stable toward wide range of mobile phase conditions, and should provide access to a
greater number of retention sites. The general types of base supports used in ionexchange chromatography include modified Silica supports, other inorganic oxides d and
organic polymers such as polystyrene divinylbenzene based. Apart from theses, silica
modified with organic polymers has also been used [13, 14].

1.2.2. Stationary phases in ion-exchange HPLC

3

Ion-exchange
chromatography

and

chromatography
anion

can

exchange

be

subdivided

into

cation-exchange

chromatography.

In

cation-exchange

chromatography positively charged ions bind to a negatively charged ion-exchange sites
whereas in anion- exchange chromatography the binding ions are negative and the
stationary phase is positive. Stationary phases for both ion-exchange chromatographies
can be further classified as either strong or weak. Strong ion-exchangers are totally
ionized across the complete operational 2-12 pH range, while weak ion-exchangers are
only charged with in a more limited pH-range [15, 16]. Table 1.1 lists the most common
functional groups on ion-exchange packing materials.
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Table 1.1. Commonly used functional groups in ion-exchange chromatography

Name

Functional group

Type

Diethylamine

―N+H(CH2CH3)2

WAX

―(CH2)2―N+H(CH2CH3)2

WAX

―O―(CH2)2―N+H(CH3)2

WAX

Polyetheleneimine

―(NH―CH2―CH2―)n―NH3+

WAX

Carboxymethyl

―CH2―COO‒

WCX

Phosphonic acid

―PO3―H‒

WCX

Selenonic acid

―SeO3‒

WCX

Quaternary amine

(CH3)4 N+

SAX

Quaternary amine

―N(CH3)2(C2H5OH)+

SAX

Sulfonic acid

―SO3‒

SCX

Diethylaminoethyl
(DEAE)
Dimethylaminoeth
anol

WAX: weak anion-exchanger; WCX: weak cation-exchanger; SAX: strong anionexchanger; SCX: strong cation-exchanger.
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1.2.3. Mobile phases in ion-exchange HPLC

In ion-exchange chromatography, the mobile phase must compatible with the
detection mode, have an appropriate pH and appropriate concentration of competing ions,
provide good selectivity for the separated sample ions, effect the charge status of the
analyte and the ion-exchanger, have the appropriate solvent strength to control the sample
retention and elution, and provide adequate solubility for the various salts and buffers
used as well as for the analyte molecules [12].

In ion-exchange chromatography the application buffer is chosen such that the
analyte

has a net charge which is opposite to the ion-exchanger functional group,

leading to its retention [17]. There are two gradient methods for separating mixture of
proteins on ion-exchange column, one is the employment of salt gradient elution- gradual
elution of the immobilized proteins from the exchanger is obtained by continuous
increase in competing ion concentration. Most often a gradient of salt such as NaCl (0 to
1M) is used for separation of proteins [17]. The salt ions compete with the proteins for
the charged binding sites. Proteins are separated based on displacement mechanism by
ions in the mobile phase competing with analyte ions for functional groups on the ionexchange resins. This method allows bound proteins to be desorbed sequentially,
according to their net charge and to be eluted from the resin consecutively.

The second gradient method is pH gradient elution. This method is used in the separation
of proteins involves a change in pH for the desorption of the protein. Changing the
mobile phase pH in the pH gradient results in decreasing the net charge of the proteins
until at the pH= pI where the protein has a net zero charge to its theoretically leading to
6

its elution. Alternatively or in addition to the changed charge status of protein, changing
the mobile phase pH can change the charge of the ion-exchanger to the neutral causing
elution of the protein. The interaction between the analyte and exchanger is negated and,
thus the protein is desorbed. This is usually used in the separation of amphoteric species,
which are separated based roughly on their pI (isoelectric point) values [17, 18].

1.3. Ion-exchange protein HPLC

Theoretical aspects and several factors involved in retention of protein have been
studied [19-21]. Proteins are large biological molecules consisting of 20 amino acids
bonded by peptide bonds between the carboxyl and amino groups of adjacent amino acid
residues. The net charge of the protein depends on the summation of the charges of the
acidic and basic amino acid groups in the proteins and charges of the N and C termini.

There is a characteristic pH called isoelectric point (pI) where the protein has no
net charge (it is neutral). The isoelectric point depends on the number, the type, and the
distribution of acidic/basic amino acids in the protein. Proteins have a net positive charge
at pH more acidic than the protein’s pI and have net negative charge at a pH more basic
than the protein’s pI.

In electrophoresis, protein separation is dependent on its net charge, with the
electrophoretic mobility of a protein being directly related to the net charge of the
protein. There are nuances however in ion-exchange chromatography. Studies have
reported that proteins being retained by an ion-exchange column at their pI values [20].
7

There are several factors explaining the difference between protein’s elution pH in ionexchange chromatography and its isoeclectric focusing pI. The important reason is that
the protein’s retention on ion-exchange column is through the interaction of only a small
portion of the protein’s surface interacting with the ion-exchanger. Proteins are three
dimensional molecules with significant diversity in the surface functional group
distribution. It is sterically impossible for all of the amino acid residues to bind to the
surface of an adsorbent. Only residues that are near the external surface of the protein can
make major contribution to protein retention. Proteins through the gradient eventually
end up binding through their strongest interaction sites. Hence it is not the charge state of
the entire protein, rather the charge state of the interacting surface regions of the protein
that influence its retention and elution [20, 21]. Thus the elution pH of a protein in ionexchange chromatography can be higher or lower than its pI. Other possible sources for
deviation from pI are Donnan potential, mixed retention mechanisms of the ionexchanger such as hydrophobic retention and anion concentration elution effects [15, 22,
23, 24]. In general most proteins elute in the pH range ±1 from its pI [24].

The limitation of ion-exchange chromatography is that proteins will be minimally
resolved that have similar net charge [25]. The resolution of proteins is high if the mobile
phase pH is closer to the pI (isoelectric point) of separated proteins which can enhance
the relative adsorption affinity of proteins [26]. When mixture of proteins is being
separated it is not possible to maintain mobile phase pH near the pI of each individual
protein because usually ion-exchange chromatography is carried out with salt gradient at
constant mobile phase pH [26]. Thus pH gradient HPLC has a significant resolution
advantage over conventional ion-exchange HPLC employing salt gradient elution.
8

1.4. Conventional Chromatofocusing

pH gradient elution in ion-exchange HPLC is often used technique because
analyte compounds in some cases cannot be sufficiently resolved well by salt gradient
elution. The first report using a pH gradient in ion-exchange chromatography in the
separation of amino acids was worked Moore et al. in 1951. This work did not draw
much attention as gradients in salt concentration or ionic strength dominated in the field.
However, in the late 1970s, pH gradient chromatographic technique called
chromatofocusing was introduced which increased the usage of pH gradient ion-exchange
chromatography in protein separation [26].

1.4.1. Background

The introduction of chromatofocusing (CF) developed by Sluyterman and co-workers in
1978 overcomes the limitations of IEC and separates the proteins near their approximate
pI values at low ionic strength [26]. Chromatofocusing is a chromatographic technique
that combines the attributes of

isoelectric focusing (IEF) and ion-exchange

chromatography performing both the separation based on pI values of proteins and band
narrowing through the generation of internal pH gradients [27, 28]. Due to its high
resolving power and ability to retain proteins in native state, CF became a widely used
analytical technique for separation of proteins [29]. This mode of chromatography
confines the time of protein exposure to extreme pH values which leads to less denature
of proteins [30].
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There are two types of chromatofocusing methods, anion chromatofocsuing and cation
chromatofocusing. Cation chromatofocusing separates proteins according to their pI
values on cation exchange column (negatively charged) presaturated with low pH elution
buffer. In this technique the column is subjected to a high pH buffer by step change
which promotes the formation of an ascending linear pH-gradient [31]. Anion
chromatofocusing employs a weak anion- exchange column which has positively charged
amine groups equilibrated with high pH application buffer to retain the negatively
charged proteins. Proteins are eluted according to their pI values by introduction of low
pH polyampholyte elution buffer through a stepwise change to the column. The elution
buffer is a mixture of polymeric buffering species that buffers a wide pH range [32, 33].
As a result of the buffering capacities and mutual titration of the mobile and stationary
phase functional groups, an outlet pH gradient in time and column pH gradient (internal
pH gradient) in distance are produced. These two pH gradients are important parameters
in protein separation.

The outlet pH gradient (pH change in time at the column outlet) affects the separation of
proteins peaks, where as the internal pH gradient (pH change in distance) provides the
focusing effect on peak widths [24]. The generation of these internal pH gradient and
outlet pH gradients can be explained by either a buffer interaction model and or an
ampholyte displacement mechanism.

In buffer interaction model, the internal pH gradient is formed inside in the column by
taking the advantage of buffering action of functional groups of ion-exchanger which
resist the sudden change in pH due to the step change. This method views the column as

10

being divided into many small sections or segments from the inlet to outlet. The shifting
of the series of mobile phase aliquots through the successive column segments followed
by the formation of equilibrium between each mobile phase aliquot pH passing and the
pH of each column segment .The pH of exiting buffer aliquot from the column is the pH
of the last segment of ion-exchanger.

For anion-exchange chromatofocusing a continuous internal pH gradient from low pH to
high pH and for cation-exchange chromatofocusing an internal pH gradient from high pH
to low pH in distance is produced entire the length of the column. The following will go
through the process of chromatography according to the buffer interaction model for
anion-exchange chromatofocusing. A protein either passes through the column with
mobile phase when it and stationary phases are similarly charged or retains by the
stationary phase when they are oppositely charged. The movement of the protein occurs
when it is exposed to a mobile phase pH=pI zone, as this zone moves through the
column. If protein would move ahead of this zone, it would become negatively charged
and be retained on the column and be eluted when the pH=pI mobile phase zone passes as
protein would become positively charged(or does not have a charge).The process of
movement of protein by continuous relocation of its pH=pI zones is repeated until the
protein exits from the column .This is the reason for focusing of proteins into narrow
peak results because protein cannot get ahead of the pH=pI band [24, 34].

The displacement mechanism also explains the generation of an internal pH gradient in
the column as well as an outlet pH gradient formation. This is met by the distribution of
mobile phase components according to the affinities for the ion-exchanger. Different
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buffer components have different affinities for the ion-exchanger. In anion
chromatofocsuing, the stronger acidic components bind the first available sites of ion
exchanger, next available sites are bound with the next strongest acidic components down
the entire column. As the elution buffer is introduced on the column, more acidic
components having higher affinity displace the less acidic components having lower
affinity, and these weaker acidic components further displace the even weaker
components [35]. This successive displacement of lower affinity (less acidity) component
by higher affinity (more acidity) component to downstream the column establishes an
ascending internal pH gradient in distance from the column inlet to outlet. As the more
acidic components successively elute from the column, the pH of the column is decreased
in time producing a descending oulet pH gradient. This displacement method promotes
the proteins to travel through the column in ampholyte bands.

The pH at the protein eluted is depending on the pH of the ampholyte band
containing that particular protein. This outlet pH gradient affects the protein elution
according to their pI values [24, 35, 36].

1.4.2. Limitations of Chromatofocusing

Although chromatofocusing yields considerable success in protein separation, it still
exhibits several limitations [24]. There is a disadvantage in using of polyampholyte
buffers in the elution buffer as these buffers are expensive and contaminate proteins. It is
very difficult to eliminate these buffers from isolated proteins as they form the complexes
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with isolated proteins [37-39]. Replacing polyampholytes by simple and common buffer
components for elution buffer causes irregularities in linear pH gradients. These pH
gradients are not smooth and are non linear, exhibiting spikes and cascade steps when
compared to pH gradients produced with polymeric buffers [40].

Another limitation is controlling the slope of pH gradient is difficult because low
mobile phase concentrations are necessary for this technique, since higher buffer
concentrations in mobile phase produce steep pH gradients because mobile phase buffer
capacity exceeds the stationary phase buffering capacity. Increased column length and
increased buffer capacity of stationary phase can leads to decreased pH gradient slope.
Increased column length gives the better separation capacity [24]. The range of pH
gradients is also often limited to small pH range as they form inconsistent gradients if the
pH range is large [8, 41]. Linear pH gradients generated on low- performance resins are
not good when compared to those produced on high-performance ion exchangers. In
chromatofocusing technique low-performance exchangers are used usually. However the
speed of analysis time is greater with high-performance chromatofocusing than lowperformance chromatofocusing is used [42].

1.5. Gradient Chromatofocusing

Gradient Chromatofocusing (GCF), a more flexible approach to chromatofocusing, has
been developed by our laboratory to overcome the major shortcomings and to broaden
the applications of conventional chromatofocusing. GCF is a chromatographgic technique
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that generates linear pH gradients using weak anion-exchange HPLC gradient pump
system with inexpensive low molecular buffer components [29, 41]. This method shows
significant advantages over conventional chromatofocusing and salt gradient ionexchange chromatography in protein separation on DEAE column. Figure 1.1 shows the
general design of gradient chromatofocusing set up. In GCF, initially a weak anion
exchange column is equilibrated with a high pH application buffer (composed of multiple
basic buffers with evenly spaced pKs). After injecting the sample, a low pH elution
buffer (composed of multiple acidic buffers with evenly spaced pK values) is mixed in
successively greater proportions with high pH application buffer to generate a linear inlet
pH gradient or external pH gradient in time prior to entering the column [8, 43]. This
inlet pH gradient is then introduced on high performance anion exchange column which
produces the internal pH gradient (column pH gradient) in distance in the column and
outlet pH gradient in time at the column outlet [44]. The formation of these two pH
gradients is explained by either buffer interaction [34] of column or by the displacement
of weaker acidic buffer components with the stronger acidic buffer components on the
column [35, 36].
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Figure 1.1. Over view of Gradient chromatofocusing technique set up
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GCF has an advantage of producing smooth linear pH gradients using simple buffer
components which is not possible in conventional chromatofocusing (although as pointed
out later this generation of smooth pH gradients takes considerable trial and error effort,
which is addressed as one of the specific aims of this project). The gradient mixing
allows gradual change in pH instead of instantaneous change in pH that a step change
causes in chromatofocusing. Gradual introduction of elution buffer onto the column gives
smooth linear and reproducible pH gradients because any disturbances or irregularities in
pH- gradients are also gradual. Li Shan and D.J.Anderson used different composition of
gradient mixing of elution buffer (%B) in single run to produce reproducible linear outlet
and inlet pH- gradients on weak anion exchange column (Protein –Pak DEAE
15HR,15µm,1000Å ) over a wide range of pH (7.5-3.5) in their work. They compared
these results with the experiments employing conventional chromatofocusing using the
same buffer components and the same packing materials. They found that the
conventional technique produced pH- gradients were too steep and not smooth which led
to poor resolution [43].

GCF has also the flexibility of obtaining required pH- gradient slope by varying the slope
of inlet pH- gradient via changing the gradient time program [29, 41, 43].
Chromatography experiments of a standard protein mixture of conalbumin, BSA, βlactoglobulin A, β-lactoglobulin B and ovalbumin using GCF shallow pH gradients
showed better resolution when compared to steep gradients [24, 45]. A high linear and
controllable outlet pH-gradients were also successfully obtained on strong anionexchange(Mono Q 4.6/100 PE ,10mm˟ 10mm,10µm) in the pH range 9.5-3.7 as well as
on different strong cation-exchange columns in the pH range of 4-10 applying the same
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GCF gradient mixing principle [46]. Reproducible linear pH-gradients from pH 8.5 to 4.0
produced on capillary Mono P column as well as on PL-SAX column [47].

Another significant advantage of GCF over CF is its flexibility in employing a wide
range of buffer concentrations by using few common buffering species without affecting
the slope of the pH-gradient for optimizing the protein separation. Shan and Anderson
generated the same linear outlet pH-gradient profiles using seven different mobile phase
systems which differ in their buffer concentrations on a Protein-Pak DEAE
polymethacrylate column (8HR, 8µm dia, 1000Å pore dia). They chromatographed a
sample mixture (pI given in parentheses) of conalbumin (5.9), BSA (4.7.4.9), ovalbumin
(4.7), β-lactoglobulin A (5.23) and β-lactoglobulin B (5.13) using the same outlet pH
gradients but generated by different buffer concentrations. Results showed a increased
resolution and decreased peak width with increased mobile phase concentration. For
instance, in the separation of β-lactoglobulin A and B, resolution is increased from 1.5 to
2.3 with the increased buffer components concentration in the elution buffer from
6.25mM to 25.0mM.The gain in the resolution of two peaks of ovalbumin in the sample
from 0.7 to 2.4 is also noticed when concentration of buffer components in the elution
buffer was increased from 6.25mM from 37.5mM [43]. The separation of five protein
mixture on Mono P column employing the gradient chromatofocusing runs at different
mobile phase concentrations (75,50,12.5mM) was also demonstrated. All five proteins
well resolved at higher buffer concentration 75mM.Improved resolution was obtained for
the separation of individual protein isoforms using higher buffer concentrations with
same column and buffer components [41]. Thomas Anderson and co-workers
reported the

influence of

also

varying buffer concentrations(5,10,20 and 40mM) on
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resolution and the peak widths of β-lactoglobulin A and B using the same outlet pH
gradients(6.8-4.3) produced on fused silica capillaries packed with PL-SAX column(
10cm x 0.32 mm i.d,10micron,1000Å).Their results showed a better resolution obtained
with 10mM buffer concentration [47].

Proteins are focused into narrow bands resulted in better peak shapes in GCF compared
to NaCl gradient IEC. Superior separation of

β-lactoglobulin A and B in GCF was

demonstrated with the optimized resolution of 2.33 compared to1.1 resolution in NaCl
gradient chromatography at constant pH using the same anion-exchange material
(Protein-Pak DEAE polymethacrylate 8HR,8µm dia,1000Å pore dia) [43]. The
separation of standard protein mixture containing cytochrome C,myoglobin, conalbumin,
β-lactoglobulin A and β-lactoglobulin B with pH gradient IEC (GCF)

was better

compared to salt gradient using the same pH gradient profile (10.5 to 3.5) [48]. Gradient
chromatofocusing of β-lactoglobulin A and β-lactoglobulin B mixture showed better
focusing capability obtaining one-third the peak width and demonstrated 3-fold resolution
gain compared to peaks of NaCl gradient ion exchange using the same Mono P column
and injecting the same amount of protein sample [41]. Results of GCF technique were
compared with the result of conventional CF technique in the analysis of the standard
protein mixture (conalbumin, BSA, β-lactoglobulin A and β-lactoglobulin B and
ovalbumin) using the same Mono P column and the same pH gradient slope. Better
resolutions and comparable peak widths achieved with GCF technique for several protein
pairs [41].
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Comparison of gradient chromatofocusing results with different columns was also
demonstrated [41, 47]. PL-SAX material has better focusing effect almost 2-fold decrease
in peak width than Mono P column in the analysis of β -lactoglobulin A and βlactoglobulin B using the same pH gradient. It was also reported that the apparent pI
values of these proteins approximately closer to their actual isoelectric poins on the PLSAX column [47]. Changing the column from DEAE to Mono P optimum resolution
increased from 2.33 to 4.19 for β-Lac A and β-Lac B and optimum peak widths decreased
from 0.076 to 0.044 for β-Lac A and 0.088 to 0.050 for β-Lac B. By applying the nearly
same pH gradient slopes, Mono P column showed greater separation compared to DEAE
column with increased resolution from 2.47 to 11.51 in the analysis of ovalbumin
isoforms and decreased peak widths for oval-1 and oval-2 from 0.11 to 0.054 and from
0.20 to 0.062 respectively [41].

Two- dimensional liquid chromatography interfaced with mass spectrometry has been
widely used potential technique for the separation of protein digested samples and
proteomic studies by performing the ion-exchange technique as the first dimension and
RP-LC as the second dimension [48, 49]. GCF has the advantage of giving an estimate of
the protein pI and being able to be directly interfaced to a mass spectrometer when
volatile buffers are used [50].

In order to expand the capabilities and advantages of the GCF, we worked out to optimize
the different aspects described in following chapters.
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CHAPTER II

IMPROVED LINEAR pH GRADIENT GENERATION IN GRADIENT
CHROMATOFOCUSING USING NOVEL APPROACH EMPLOYING
BRIDGING BUFFERS

2.1. Introduction

Gradient chromatofocusing (GCF) is a chromatographic technique developed by
the Anderson group that generates linear pH gradients using weak anion-exchange HPLC
with inexpensive low molecular buffer components [1-4]. Other groups referred it as pHgradient ion-exchange chromatography in their articles [5, 6]. In GCF an elution buffer
(consisting of multiple acidic buffers with evenly spaced pKa values) is mixed in
successively greater proportions with application buffer (composed of multiple basic
buffers with evenly spaced pks), to generate a pH gradient in time prior to entering the
column. GCF utilizing linear pH gradients provides unique capabilities in pI- based
26

protein separation when compared with the conventional ion-exchange and conventional
chromatofocusing chromatography.It also has optimization advantages over conventional
chromatofocusing through its ability to manipulate the pH gradient profile by changing
the slope of the external pH gradient and the flexibility in employing a wide range of
buffer concentration [3]. Increased resolution and decreased peak widths are achieved by
this technique in protein separation [3,4]. Expensive polymeric ampholyte buffers used in
conventional chromatofocusing are replaced by less expensive common buffer
components to produce linear pH-gradients [1-4].

An objective of the pH gradient ion-exchange chromatography is to separate the
complex mixture of biomolecules with high resolution using controllable and
reproducible linear pH gradients. Formation of pH gradients prior to the column by
proportioning pumps allows the generation of pH-gradients with slopes that are
independent of the buffer concentration. The slope of the pH gradient plays a pivotal role
in both the retention time of as well as band width of the protein peak.

Generation of smooth linear pH gradients requires considerable trial and error effort.
Work on generating linear pH gradients on weak anion-exchange columns has been
reported by our group [1-4]. Liu and Anderson attempted to produce a linear pH gradient
ranging pH from pH 7.4 to 3.5, however shape of the pH-gradient is not totally linear or
smooth [1]. Shan and Anderson had to use five different gradient time programs to
produce reproducible linear pH gradients over the same pH range 7.5-3.5 when using
seven different buffer systems differ in their concentrations [3]. They had to use complex
gradient time programs when high buffer concentration mobile phases were used.
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Irregularity was noted between 7.1-6.5 pH regions of the pH gradients [3]. In another
study by our group a linear pH gradient from pH 9-2.6 was accomplished to separate
proteins for on-line mass spectrometric analysis [7]. The gradient program used to
generate the outlet pH gradient (9-2.6) was a complicated six step gradient time program.
There were also irregularities at several pH regions of this gradient.

In work done by others on weak anion-exchangers a pH gradient within the pH range 8.54.0 was produced

using low molecular buffer components [8]. Different gradient

programs were used to obtain linear pH gradients in this work. However a sharp drop was
observed in the pH 8.5-7.7 region of the gradients and the shape of the pH gradients was
concave from pH 7.5-5 for two of the three pH gradients [8].

Several studies have employed pH gradients on strong anion-exchange columns in the
analysis of proteins. A pH gradient from pH 10.5 to 3.5 separated a standard protein
mixture using different buffer components with different concentrations employing
multiple linear gradient steps programs [9]. However the generated pH gradient was
curved and irregular. Another study reported the separation of MnP isozymes utilizing a
6.0-4.0 pH gradient in a linear 0-100%B gradient program [10]. The resulting pH
gradient showed a precipitous drop and a concave shape from pH 6-5 after the plateau
region. T.Ahmed and his co-workers generated various pH gradients ranging from 11.54.0, 10.5-4.0, 10-4 and 8.7-3.7 [5]. The shapes of these pH gradients were irregular with a
sudden laege drop after the plateau regions of the gradients. In another work a decreasing
linear pH gradient (pH range 10-4) was produced for the anion-exchange
chromatography of a monoclonal antibody from hybridoma cell culture supernatant using
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the 20mM buffer components. The resulting pH gradient showed shallowness after the
irregular plateaued region of the gradient. [6].

Formation of pH gradients on cation-exchange columns have also been reported in
chromatography of

proteins. Farnan and Moreno showed sensitive separation method

utilizing a pH gradient (6-9.5) generated to separate monoclonal antibodies [11]. In their
work they studied the effect of altering the relative amounts of the buffer components and
also the effect of changing the concentration of the buffering species in the formation of
pH gradients via 0-100% linear gradient elution program. These gradients had the shapes
of a large peak increasing from pH 6 to a maximum pH 9 abd then dropping back to a pH
6.

Generation of pH gradients on all types of ion-exchange columns (porous and non
porous, strong and weak, anionic as well as cationic) over a pH range from 2.4-10.8 was
done by employing 4mM basic buffer components in both application and elution buffers
through 0-100%B linear gradient program [12]. The pH gradients produced on non
porous weak anion-exchange columns were irregular and not controllable. For the porous
anionic (weak and strong) and cationic (weak and strong) columns, two of the four pH
gradients were fairly linear while the other two showed irregularities in several pH
regions of the gradients. Review of the literature thus confirms the difficulty in
generating smooth linear pH gradients in ion-exchange HPLC.

In the present study smooth linear pH-gradients were generated with simpler gradient
programs by using a new approach involving bridging buffers. In this approach the
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highest pKa acidic buffer component is added in the basic application buffer and the
lowest pKa basic buffer component is included in the acidic elution buffer.

2.2. Experimental

2.2.1. Materials

Bis-tris methane (catalog no. A0293971) was from Fisher (New Jersey, USA). 2, 3dimethyl pyridine (catalog no. L3501), acetic acid (catalog no.695092), lactic acid
solution (catalog no.252476), 4-methylpyridine (catalog no. 239615), pyridine (catalog
no. 270970), 4-chlorophenyl acetic acid (catalog no. 139262) were purchased from
Sigma-Aldrich (St.Louis, MO, USA). Conalbumin (catalog no.C-0755), rat albumin
serum (catalog no. A6272), β-lactoglobulin A (catalog no. L7880), methanol (catalog
no.14262) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Bulk anionexchange material wasProtein-Pak DEAE 8HR, 8µm diameter, 1000 Å pore diameter,
DEAE functionalized polymethacrylate) from Waters (Milford, MA, USA). HPLC grade
water was generated by a Barnstead Nano system with a Nanpure Diamond Pack Organic
Free DI cartridge from Thermo Scientific (West Palm Beach, FL, USA). All the solvents
were filtered through 0.45µ cellulose ester membrane filters from Millipore (Billerica,
MA, USA).

In buffer system IA, mobile phase A (high pH application buffer) consisted of 10mM of
each 2, 3-dimethyl pyridine (6.57), and 3-methyl pyridine (5.68). Mobile phase B (low
pH elution buffer) consisted of 10mM of each acetic acid (4.76) and lactic acid (3.81), 230

hydroxy benzoic acid (2.97). In buffer system II, application buffer A (high pH buffer)
consisted of 10 mM of each 2, 3- dimethyl pyridine (6.5), 4-methyl pyridine (6.02), 3methyl pyridine (5.68), and pyridine (5.25). Elution buffer B (low pH buffer) composed
of 10 mM of each acetic acid, 4-chlorophenyl acetic acid (4.19), and lactic acid. The pKa
of each buffer component is given in the parentheses.

2.2.2. Chromatographic conditions and pH gradient measurement

The HPLC system consisted of a System Gold 126 solvent module gradient pump
system, System Gold 508 Auto Sampler, System Gold 168 Detector from Beckman
instruments (Fullerton, CA, USA). All the data collected and analyzed using 32 Karat
Gold software (version 8). ). DEAE anion-exchange column (4.6 X 100 mm, 8HR, 8µ,
1000Å). The pH gradient was monitored online after the detector using a FC45C flow
cell equipped with a flow-through pH electrode (from Sensorex, S450CD).The volume of
the pump mixing chamber to the column was 0.8 mL and the void volume of the column
was 0.33 mL. The flow rate of the mobile phase was 1.0 mL/min. The sample injection
volume was 100uL. The column was equilibrated for 50 min with the application buffer
prior to the start of each run till the column pH reaches the pH of the application buffer.

The pH gradients were monitored on-line after the detector by collecting pH
measurements using a FC45C flow cell (200uL) equipped with a flow-thru pH electrode
from Sensorex (S450CD) that connect directly to the tubing used by HPLC system. A
Denver Instrument pH meter (Model 250) with data logging capabilities was interfaced
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by the micro flow-thru electrode for data acquisition every two minute intervals. The
micro flow-thru electrodes allow the pH measurements at the low flow rates (100
uL/min).These electrodes are advantageous because they measure pH on-line in no time
as opposed by taking the pH measurements over time by collecting fractions. This
process eases the laborious efforts that were once required to measure pH of the fractions
manually in development of linear gradients.

2.3. Results and discussion

Generation of pH-gradients is crucial to the separation of proteins because it
largely determines the quality and usefulness of the separation. A pH-gradient that is
appropriate to the separation can be generated when the slope, shape and range of the pHgradient should be well controllable. The pH-gradient should be reproducible, linear and
smooth as this largely determines the resolution of the separation. Experiments were done
to get smooth linear descending pH-gradients without a column in place by delivering
different proportions of application and elution mobile phases by HPLC gradient pumps.
In these experiments trial and error gradient programming was done using the buffer
system IA. The buffer components of buffer system IA is given in Table 2.1. But the
resulted pH gradients were irregular in some pH regions and showed poor linearity with
pH range from 8.5 to 2.5.
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Table 2.1. Buffer components used for buffer system IA

Basic application

Acidic elution

buffer(10mM)

buffer(10mM)

2,3-dimethyl

Acetic acid (4.76)

pyridine (6.57)
3-Methyl Pyridine

Lactic acid (3.81)

(5.68)
2,5-dihydroxybenzoc
acid (2.97)
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2.3.1. Development of linear pH gradients by manipulation of gradient programs

Achieving good linearity with a smooth slope in the pH-gradients is a labor
intensive and time consuming process. Figures 2.1, 2.2 and 2.3 show the formation of
poor pH gradient using dead volume union in place of a column generating a pH gradient
employing different pump-proportioned external mixing of increasing elution buffer
mixing with decreasing amounts of application buffer, both containing 10 mM of 2,3dimethyl pyridine (pka 6.57), 10 mM of 3-Methyl pyridine (5.68), 10 mM acetic acid
(4.76), 10 mM of lactic acid and 10 mM of 2,5-dihydroxy benzoic acid (2.97) . The pka
values of these buffering species are evenly spaced (approximately 1) throughout the pH
range 8.5-2.5.

In Figure 2.1, pH gradients a, b and c were produced with a 0%-100%B linear
gradient program for different length of gradient times by delivering a different
percentage of mobile phase per minute. The resulting pH gradients were irregular. The
pH gradient plot a in Figure 2.1 showed a drop in pH at the beginning first three minutes,
shallowness in the mid pH region followed by a short steep portion and ending with a
more shallow pH gradient. To improve the linearity, the rate of gradient change in the
problematic region was varied as given in plots b and c in Figure 2.1. Although the
increased gradient rate did eliminate some of the first plateau region in the gradient (pH
range 7.2-6.7), a significant plateau region still remained.
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Figure 2.1. Non-linear pH-gradients formed by buffer system IA without column.
Gradient time programs used are 0-100%B in 60min, 40 min and 28 min for a, b,
and c pH-gradients respectively
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To achieve better linear pH gradients without plateau regions, multiple slope time
gradient steps were incorporated into the program as opposed to previously used one
slope 0-100% B linear gradient time program. The established pH gradient profiles with
these multi step programs are shown in Figure 2.2 The first attempt (plot a) utilized
program that generated a precipitous drop in the pH from 8 to 4 after a long plateau
region followed by irregularity at the end portion of the gradient. The mobile phase
mixing rate was 2.5% / min (plot a in Figure 2.2). In order to correct slope of the pH
gradient, higher gradient was attempted to deal with beginning plateau and mid regions.
The modified mobile phase rates throughout the pH gradients were 3.33% / min (plot b in
Figure 2.3), 3.4% / min - 3.57% / min – 3.7% / min (plot c in Figure 2.3); 3.58% / min –
3.8% / min – 3.57% / min (plot d in Figure 2.3).
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Figure 2.2. Non-linear pH gradients formed by without column with buffer system
IA. Gradient time programs used for (a) 0%-100% B in 15 min, 40-70%B in 10
min, 70-100%B in 15 min; (b) 0%-2% B in 1 min, 2-22%B in 6 min, 22-32%B in
3min, 32-53%B in 14 min, 53%-100%B in13.5 min (c) 0-20.4% B in 6 min, 20.446.4% B in 7 min, 46.4-100% B in 15.7 min; and d) 0%-17.9% B in 5 min, 17.952.1% B in 9 min, 52.1% B-100% B in 13.4 min
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These modified time programs did not yield a completely linear pH gradient. In
general these pH gradient profiles were steeper in the first three minutes, shallow from 3
to 10 min followed by a concave shape.

Other multiple linear step gradient programs were then attempted to eliminate the
irregularity in the pH gradients, however the slope at the beginning pH region of the
gradients could not be controlled. The resulting pH gradients (plots a, b and c) are given
in Figure 2.3. In these experiments attempts were made to decrease the shallowness of the
mid pH regions as well as decrease the steepness of the pH gradients (plots a and b in
Figure 2.3) by giving the mobile phase at faster rates. The gradient program resulting in
plot c (Figure 2.3) pH gradient yielded the best resulting however the pH gradient still
had a steeper drop in mid region.
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Figure 2.3. Nonlinear pH-gradient formation with buffer system IA without column.
Gradient time program were (a) 0-100% B in 28 min (b) 0-20% B in 6 min, 20% B50% B in 6 min, 50% B-100% B in 15 min (c) 0-10% B in 3 min, 10-30% B in 4min,
30-66% B in 6 min, 66% B-100% B in 10 min
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These multiple step gradient trials by varying the gradient rate continuously at
different time periods of the pH gradient were not able to yield a smooth linear gradient.

2.3.2. Improved linear pH-gradient generation by bridging buffer components
between basic application buffer and acidic elution buffer

A new approach to generate linear pH- gradients has been worked out. As
discussed above attempt to achieve smooth linear pH gradient by varying gradient rate is
a very laborious process that does not produce completely linear pH gradients. This
approach does not address the inherent problem that lack of buffering capacity in mid
pH gradient regions due to there being progressively less application buffer and
successively more elution buffer in the mid region. This leads to a sudden drop in pH
even though the pKa of buffer components are evenly spaced. This reduced buffering
capacity leads to the noted irregularities in the pH gradients.
The problem was solved by introducing “bridging” buffers components between
application buffer and elution buffers. The composition of buffer systems IA was
modified by adding the lower pKa application buffer component to the elution buffer and
high pKa elution buffer component to the application buffer. This bridging of the
application and elution buffer solutions leads to sufficient buffer capacity throughout the
desired pH range which results in smooth linear pH-gradients. The buffer system in Table
2.1 was modified by adding the 5mM of acetic acid (pka=4.76) to the application buffer
and 5mM of 3-methyl pyridine (pka=5.68) to the elution buffer. This modified buffer
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system IA (Table 2.2) produced an excellent linear pH gradient with a simple 0%B100%B linear gradient program as given in Figure 2.4.

Adding the high pKa elution buffer component to the application buffer lower the
pH of the application buffer while at the same time adding the low pK a elution buffer
component increased the pH of the elution buffer. The pH range of the gradient decreased
from 8.5-2.5 to 6.7- 3.0 by adding the 5mM acetic acid to application buffer and 5mM of
3-methyl pyridine to the elution buffer that can be observed in Figure 2.4.
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Table 2.2. The modified buffer system IA with bridging

Basic application

Acidic elution buffer

buffer
( each component10mM)
(each
component10mM)
2,3-dimethyl pyridine

Acetic acid (4.76)

(6.57)
3-Methyl Pyridine

Lactic acid (3.81)

(5.68)
2,5-dihydroxybenzoc acid
(2.97)
Bridging (5mM

Bridging (5mM)

Acetic acid (4.76)

3-methyl pyridine (5.68)
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Figure 2.4. The pH gradient profile produced with bridging buffer system IA with

0-100% B in 30 minutes (3.33%/ min) without column in place
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2.3.3. Generating smooth linear pH gradient with buffer system II A

This bridging technique has also been utilized to generate smooth linear pHgradient without the column with the buffer system IIA which has more buffer
components compared to buffer system I. Buffer system IIA is given in Table 2.3. pKa
values of these buffering species are evenly spaced (approximately 0.5) over the entire
pH range from 6.7 to 2.5. Figure 2.5 shows the linear pH-gradient profiles with buffer
system IIA with bridging and without bridging. The buffer component 4-chlorophenyl
acetic acid is only partially soluble in water. Thus 5% methanol was used in the
application and in the elution buffer of buffer system IIA with and without bridging.
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Figure 2.5. pH gradients produced by buffer system IIA with no column in place (A)
without bridging and (B) with bridging. Gradient programs were used for (A) and
(B) 0% -100% B in 30 min
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Table 2.3. Buffer components used for Buffer system IIA without bridging and with
bridging.

Without bridging

With bridging

(each component 10 mm)
Elution
Applica
buffer
tion
buffer

2,3dimethy
l
pyridin
e(6.57)

4methyl
pyridin
e (5.68)

3methyl
pyridin
e (5.68)

Pyridin
e (5.25)

(each component 10 mm)
Application
buffer

2,3-dimethyl
pyridine(6.57
)

Acetic acid
(4.76)

4chlorophen
yl

4-methyl
pyridine
(6.02)

acetic acid
(4.19)

Elution buffer

Acetic acid
(4.76)

4- chlorophenyl
acetic acid (4.19)

Lactic acid
3-methyl
pyridine
(5.68)

(3.81)
2, 5dihydroxy
benzoic
acid (2.97)

Pyridine
(5.25)

Bridging
(5mM)
Acetic acid
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Lactic acid
(3.81)
2, 5-dihydroxy
benzoic acid
(2.97)

Bridging (5mM)
Pyridine

2.3.4. Producing linear pH-gradient profiles on weak anion-exchange column
(DEAE column)

After attaining the linearity of the pH gradients for the two buffer systems (IA &
IIA) without column in place, experiments were done for generating linear pH-gradients
on the DEAE.

Non-linearity in the pH-gradient was noted in column studies employing the
bridging buffer system given in Table 2.2. The same application and elution buffers were
used as previously used without column to produce linear pH gradients (Figure 2.4). But
there were drops in pH from 36 min to 38 min at the end region of pH-gradients which
can be observed in Figure 2.6 (plot a). Since the drop in pH was in the 3.9 to 3.35 pH
range, the region at which lactic acid buffer (pka 3.81), lactic acid concentration was
successfully increased from 10 mM to 15 mM, to 20 mM. The resulting pH gradients,
however, did not improve as shown in Figure 2.6. The possible reason for not achieving
linearity in the end region of the pH gradient is the strong retention of the most acidic
component 2, 5-dihydroxy benzoic acid in its anionic form on the column. The strong
retention of the anion of 2, 5-dihydroxy benzoic acid displaces the anionic form of lactic
acid on the column where it combines with H+ in the mobile phase leading to decrease in
pH.
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Figure 2.6. Lactic acid concentration increased from 10mM (a) to 15 mM (b) and
20mM (c), 2, 5-dihydroxy benzoic acid concentration decreased from 10mM to 5mM
(d). Gradient program used was 0-100%B in 40 min.
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Eventually the anoinc form of the lactic acid are displaced and there is limited binding
of anionic form of 2, 5-dihydroxy benzoic acid (anion-exchanger sites filled up), so then
the pH drops rapidly to the elution buffer pH. The 2, 5-dihydroxy benzoic acid was
removed from the elution buffer to eliminate this non-linear pH drop at the end region of
the pH-gradient. Gradients of the resulting modified buffer system IA of Table 2.2 and
the buffer system IIA (Table 2.3) without 2, 5-dihdroxy benzoic acid, pH gradients were
then run on DEAE ion-exchanger with and without bridging. The resulting pH gradients
are shown in Figures 2.7 and 2.8. The outlet pH gradients produced without bridging had
a precipitous drop after the beginning plateau region and showed irregularity throughout
the pH gradient. The bridging buffer system however yielded a smooth linear pH
gradient. The same results were obtained for Buffer System IIA without 2, 5-dihdroxy
benzoic acid are given in Figure 2.8.
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Figure 2.7. Outlet pH gradient on DEAE column generated from 0-100% B gradient
of Table 2.2 buffer system IA without 2, 5-dihdroxy benzoic acid without bridging
(A) and with bridging (B)
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Figure 2.8. Outlet pH gradient on DEAE column generated from 0-100% B gradient
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Finally of separation standard proteins were run employing the gradient of
bridging buffer system IA (Table 2.2) and IIA (Table 2.3) both of which had the buffer
component 2, 3-dimethyl pyridine. It was found that several of protein peaks were
missing (either from irreversible adsorption or precipitation of the proteins). It was found
that removal of the 2, 3-dimethyl pyridine replaced with bis-tris methane in the
application buffers solved the problem. The final buffer systems (buffer system I B and
buffer system II B) that yielded excellent linear pH gradients which were compatible with
the protein chromatography are given in Table 2.4, with the resulting linear pH gradients
plotted in Figure 2.9.

2.4. Conclusion

This new way of generating linear pH-gradients by incorporation of bridging
buffer components in the application and elution buffers eliminates non-linear drops in
pH that are problematic in current gradient HPLC techniques, producing well controlled
and reproducible linear pH-gradients.
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Table 2.4. Composition of optimized bridging buffer systems I B and II B

Buffer System I B

Buffer system II B

(each component 10 mM)
Application
Elution
buffer
buffer
(pKa)
(pKa)

(each component 10 mM)
Application
Elution
buffer
buffer
(pKa)
(pKa)

Bis-tris
methane
(6.5)

Acetic
acid
(4.76)

Bis-tris
methane
(6.5)

Acetic acid
(4.76)

3-methyl
pyridine
(5.68)

Lactic
acid

4-methyl
pyridine
(6.02)

4chlorophenyl

(3.81)

acetic acid
(4.19)
Lactic acid
(3.81)
3-methyl
pyridine
(5.68)

Pyridine
(5.25)

Bridging
(5mM)

Bridging
(5mM)

Bridging
(5mM)

Bridging
(5mM)

Acetic acid

3-methyl
pyridine

Acetic acid

Pyridine

A
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Figure 2.9. Outlet pH gradients on DEAE column generated from 0-100% B
gradient of Table 2.4 buffer systems IB (A) and IIB (B) with bridging
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2.5. Separation of protein mixture on pH gradients produced with bridging and
without bridging with buffer system IB

The results of pH gradient generated without bridging are compared with the
results of pH gradient produced with bridging with buffer system IB in the
chromatographic separation of three protein mixture of conalbumin (pI = 5.9), rat
albumin (pI = 5.7), and β-lactoglobulin A (pI = 5.13) on DEAE weak anion-exchange
column(same column used for generating pH gradients). Results showed pH gradients
generated with bridging buffer system IB gave significantly higher resolutions of the
proteins compared to non-bridging buffer system IB. Gradients for each are shown in
Figure 2.10. Resolutions increased with the bridging buffer system significantly from 3.5
to 8.26 for conalbumin and rat albumin and 1.6 to 3.02 for rat albumin and βlactoglobulin A pairs, as summarized in Table 2.5. A two-fold gain in the average
resolution from 2.5 to 5.6 was obtained for the bridging buffer system compared to
without bridging buffer system.
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Table 2.5. Resolution and peak widths of proteins with and without bridging for
gradients generated with buffer system IB

Resolution(Rs)
Buffer System IB
Proteins
Without bridging

Conalbumin
and Rat
albumin
Rat albumin
and βlactoglobulin
A
Average

Proteins

With bridging

3.5

8.26

1.6

3.02

2.55

5.64

Peak widths at half

Peak widths in pH units

height (min)

Buffer system IB

Buffer system IB

Conalbumin
Rat albumin
βlactoglobulin
A

Without
bridging

With
bridging

Without
bridging

With
bridging

2.19
1.37
1.21

2.08
1.48
1.58

0.38
0.32
0.12

0.15
0.13
0.08
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Figure 2.10. Outlet pH gradients on DEAE column generated from 0-100% B
gradient of buffer systems IB without bridging (A) and with bridging (B)
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A

B

Figure 2.11. Chromatogram of a sample containing conalbumin, rat albumin, and βlactoglobulin A with bridging (A) and without bridging (B) with buffer system IB
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CHAPTER III

The effect of the number of buffer components on separation of proteins in highperformance gradient chromatofocusing ion-exchange using linear pH-gradients

3.1. Introduction
Background discussion on gradient chromatofocusing (GCF) is covered in section
1.6 of Chapter 1. Studies of the effect of gradient slope and buffer concentration [1-3]
have been done, showing that these experimental factors are important in the
optimization of the chromatography. This gives GCF significant advantage over
conventional chromatography which cannot control these factors. In the present study the
effect of number of buffer components resulting in more closely spaced pKas in the
gradient is studied.
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3.2. Experimental
3.2.1. Materials and injected samples
Conalbumin (catalog no.C-0755), β-lactoglobulin A (catalog no. L7880), methanol
(catalog no.14262), β-lactoglobulin B (catalog no. L8005), ovalbumin (catalog no. A2512), bovine albumin serum (catalog no. A5503), were purchased from Sigma-Aldrich
(St. Louis, MO, USA). All proteins samples were prepared in deionized water and 100
uM of each protein was injected.

Bulk anion-exchange material wasProtein-Pak DEAE 8HR, 8µm diameter, 1000 Å pore
diameter, DEAE functionalized polymethacrylate) from Waters (Milford, MA, USA).
HPLC grade water was generated by a Barnstead Nano system with a Nanpure Diamond
Pack Organic Free DI cartridge from Thermo Scientific (West Palm Beach, FL, USA).
All the solvents were filtered through 0.45µ cellulose ester membrane filters from
Millipore (Billerica, MA, USA).

3.2.2. Chromatographic conditions on DEAE column

The HPLC system consisted of a System Gold 126 solvent module gradient pump
system, System Gold 508 Auto Sampler, System Gold 168 Detector from Beckman
instruments (Fullerton, CA, USA). All the data collected and analyzed using 32 Karat
Gold software (version 8). DEAE anion-exchange column (4.6 X 100 mm, 8HR, 8µ,
1000Å). The pH gradient was monitored online after the detector using a FC45C flow
cell equipped with a flow-through pH electrode (from Sensorex, S450CD).The volume of
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the pump mixing chamber to the column was 0.8 mL and the void volume of the column
was 0.33 mL. The flow rate of the mobile phase was 1.0 mL/min. The smaple injection
volume was 100uL. The pH gradients and proteins were monitored at 280nm. The
column was equilibrated for 50 min with the application buffer prior to the start of each
run till the column pH reaches the pH of the application buffer.

The pH gradients were monitored on-line after the detector by collecting pH
measurements using a FC45C flow cell (200uL) equipped with a flow-thru pH electrode
from Sensorex (S450CD) that connect directly to the tubing used by HPLC system. A
Denver Instrument pH meter (Model 250) with data logging capabilities was interfaced
by the micro flow-thru electrode for data acquisition every two minute intervals. The
micro flow-thru electrodes allow the pH measurements at the low flow rates
(100uL/min).These electrodes are advantageous because they measure pH on-line in no
time as opposed by taking the pH measurements over time by collecting fractions. This
process eases the laborious efforts that were once required to measure pH of the fractions
manually in development of linear gradients.

Buffer system IB consisted of an application buffer mobile phase A composed of 10mM
of bis-tris methane (6.5), 10mM of 3-methyl pyridine (5.68) and 5% methanol, adjusted
to pH 6.5 with concentrated ammonium hydroxide and an elution buffer mobile phase B,
consisting of 10mM of acetic acid (4.76), 10mM of lactic acid (3.81) and 5% methanol,
without any pH adjustment. Buffer system IIB consisted of an application buffer mobile
phase A composed of 10mM each of bis-tris methane (6.5), 4-methyl pyridine (6.02), 3-
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methyl pyridine (5.68), pyridine (5.25) solution and 5% methanol with the pH adjusted to
6.5 using concentrated NH4OH.

An elution buffer mobile phase B, consisting of 10mM each of acetic acid (4.76), 4chlorophenyl acetic acid (4.19), lactic acid (3.81) and 5%methanol, without any pH
adjustment. The pKa values for the buffer components are given in parentheses.

3.2.3. Chromatographic conditions on commercial PEI weak-anion exchange
column

PEI weak anion- exchange column (50 X 2.1 mm, 5µ, 300Å) was purchased from
The Nest group (Columbia, MD 21045, USA). The flow rate was 0.3 mL/ min.
Chromatographic conditions are the same as indicated in section 3.2.2.

3.3. Results and Discussion

3.3.1. Superimposition of pH-gradients generated with two buffer systems

Reproducible, excellent linear pH-gradients using bridged buffer system IB and
buffer system IIB was achieved, as presented in Chapter 2. These buffer systems differ in
their number of buffer components. Since buffer system II has more number of buffer
components, different gradient time programs were used for buffer system II to achieve
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the superimposition with buffer system I by trial and error gradient mixing of buffer
components.

The effect of the number of buffer components in the mobile phase buffer was
studied on resolution and peak width of protein separation. Buffer system with more
buffer components had buffer species added to the buffers such that there was smaller
pKa difference between buffer components. In order to study this effect, pH-gradients
needed to be matched exactly such that difference in chromatographic separation
characteristics could be attributed solely to difference in number of buffer components.

Numerous trials were done to exactly match the pH gradients of the two buffer
systems. The optimized gradient programs and the resulting pH gradients for the two
buffer systems are shown in Figure 3.1, in which shows that exact superimposability of
the gradients was achieved.
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Figure 3.1. Superimposable pH-gradients of buffer system I (A) and buffer system
II (B). The gradient time programs used for buffer system I (A): 0 -62.7% B in 22
min, 62.7 -78% B in 6 min, 78-100% B in 7.09 min and for buffer system II (B) 0 45.19% B in17min, 45.19 -60.03% B in 6 min, 60.03-81.03% B in 6 min, 81.03-93%
B in 14.59 min.
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3.3.2. Comparing the buffer systems IB and IIB in the GFC separation of proteins
on the DEAE column
Chromatographic separation experiments of five standard proteins β-lactoglobulin
A (5.13), β-lactoglobulin B (5.34) ,bovine albumin serum (4.9), conalbumin (5.9) and
ovalbumin (4.6) were done on DEAE weak anion-exchange column employing the
superimposed linear pH-gradients given in Figure 3.1 for the two buffer systems (protein
pIs are given in the parentheses). Comparison of the GCF chromatograms for the two
buffer systems are given in Figures 3.2, 3.3 and 3.4.

67

Figure 3.2. GCF chromatography of β-lactoglobulin A and B with two buffer
systems IB (upper plot) and IIB (lower plot) on DEAE column.
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Figure 3.3 . GCF chromatography of bovine serum albumin with two buffer
systems IB (upper plot) and IIB (lower plot) on DEAE column.
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Figure 3.4. GCF chromatography of conalbumin and ovalbumin with two buffer
systems IB (upper plot) and IIB (lower plot) on DEAE column.
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3.3.2.1. Peak widths results

Results showed that all the proteins were focused into narrower bands with the
more component buffer system II compared to the less component buffer system I as
summarized in Table 3.1. The greatest decrease in peak width was seen for bovine
albumin serum which decreased in peak width at half height from 2.69 min to 0.7 min
and for β-lactoglobulin B which decreased from 1.11 min to 0.5 min.
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Table 3.1. Comparison of the peak widths at half height of proteins separated with
linear pH gradients (Figure 3.1) of buffer system IB and buffer system IIB on DEAE
column

Peak widths at half height(min)
Protein

Buffer
system II

Buffers
system I

Peak widths in pH units
Buffers
system I

Buffer
system II

Conalbumin

1.78

1.4

0.3

0.18

Ovalbumin

0.71

0.46

0.4

0.3

Bovine albumin serum
β-lactoglobulin B
β-lactoglobulin A

2.69
1.11
1.24

0.7
0.5
0.94

0.32
0.18
0.73

0.09
0.18
0.19

Average

1.50

0.78

0.39

0.18

Median

2.69

0.7

0.32

0.09
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3.3.2.2. Resolution results

Resolutions were calculated for different protein pairs using the data of
individually chromatographed proteins. The resolution for each protein pair is calculated
using following equation:

where Rs is the resolution; tR2 and tR1 are the retention times of peak 2 (late eluting
peak) and peak 1 (early eluting peak) respectively, and Wh2 and Wh1 are the width of
peak 2 and peak 1 at half height respectively.

Resolutions were found to be higher for four of the five proteins in their GCF
separation using buffer system IIB (more buffer components) compared to buffer system
IB (less buffer components). For example the resolution increased from 4.7 to 10.3 and
0.3 to 0.6 for BSA and conalbumin and BSA and ovalbumin pairs, respectively. The
resolution of the various adjacent eluting protein pairs are given in Table 3.2.
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Table 3.2. Comparison of resolution of proteins separated with linear pH gradients
(Figure 3.1) of buffer system IB and buffer system IIB on DEAE column

Resolution (Rs)
Buffer

Buffer

system I

system II

8.8

10.5

BSA & Ovalbumin

0.3

0.6

β-lactoglobulin

0.3

0.5

1.74

1.6

4.708

10.3

Proteins

Ovalbumin&Conal
bumin

B& BSA
β-lactoglobulin
B&
β-lactoglobulin A
BSA &
Conalbumin
Average

3.16

4.7

Median

1.74

1.6
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3.4. Chromatographic separation of three standard proteins on commercial PEI
weak anion-exchange column
Chromatographic separation of conalbumin, β-lactoglobulin A, and βlactoglobulin B was carried out on commercially purchased PEI weak anion- exchange
column (50 X 2.1 mm, 5µ, 300Å) employing the same superimposed pH gradients
generated with buffer system IB and buffer system IIB.

3.4.1. Peak width and resolution results

The results of protein peak widths at half height and resolutions resulting from the exact
same pH gradient runs employing buffer system IB and buffer system IIB on the PEI
commercial column are given in Table 3.3 and Table 3.4. Results show a significant
effect of number buffer components on peak widths and resolution. Proteins were
focused into narrow bands with buffer system II. Peak widths decreased between 15 –
31% in comparing buffer system IB and system IIB results (Table 3.3). The resolution
increased from 11.2 to 18.0 and from 1.05 to 5.8 in the separation of β–lactoglobulin B &
conalbumin and β –lactoglobulin B and β –lactoglobulin A, respectively, in comparing
buffer system IB with buffer system IIB, respectively (resolution increases with more
buffer components).
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Resolutions and peak widths at half height are also compared between packing column to
commercially purchased column for conalbumin, β-lactoglobulin A, and β-lactoglobulin
B for both buffer systems IB and IIB. The average peak widths at half height significantly
decreased as shown in Table 3.3, more than 50% from 1.37 to 0.67 for buffer system I
and from 0.94 to 0.54 for buffer system II for the PEI commercial column compared with
the DEAE column. The average resolutions for the PEI commercial column compared
with the DEAE column were increased from 4.96 to 6.10 for buffer system IB and from
10 to 12 buffer system II in the chromatography of conalbumin, β-lactoglobulin A, and βlactoglobulin B with buffer system IIB as shown in Table 3.4.
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Table 3.3. Comparison of the peak widths at half height of proteins separated with
linear pH gradients of buffer system IB and buffer system IIB on commercial PEI
and DEAE columns

Proteins

Peak widths at half height(min)

Buffer System IB

Buffer System IIB

Commercial

Packed

Commercial

Packed

column
1.16

column
1.78

column
0.99

column
1.4

β –lactoglobulin B

0.40

1.11

0.33

0.5

β –lactoglobulin A

0.45

1.24

0.31

0.94

Average

0.67

1.37

0.54

0.94

Conalbumin
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Table 3.4. Comparison of resolution of proteins separated with linear pH gradients
of buffer system IB and buffer system IIB on commercial PEI and DEAE columns

Proteins

Resolutions (Rs)

Buffer System IB

β-lactoglobulin B
&
Conalbum
in
β -lactoglobulin A
& βlactoglobu
lin B
Average

Buffer System IIB

Commercial

Packed

Commercial

Packed

column
11.16

column
8.18

column
18.04

column
18.4

1.05

1.74

5.8

1.6

6.10

4.96

12

10
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The reasons for obtaining improved resolution and narrower peak widths for
commercially purchased PEI anion exchange column (2.1 x 50 mm, 5µ, 300Å) when
compared to self packing DEAE column (4.6 x 100 mm, 8µ, 1000Å) are the different
particle diameters used and difference in the packing of two columns. Packing material
particle size (dp) is a physical dimension that has significant influence on the
performance of an HPLC column. Smaller particle sizes give higher peak efficiencies.
Factors affecting resolution include selectivity, retention capacity, and efficiency. A
column’s particle size particularly affects the efficiency term of the resolution equation.
Efficiency is quantified by the number of theoretical plates (N) in a given column. A
theoretical plate refers to one complete equilibrated transfer (or partition) of a solute
between the mobile and stationary phases. Efficiency, as measured by the number of
theoretical plates (N), inversely related to the particle size (dp) as given by the well
known van Deemter equation:
H = L/N = A*dp + B/v + C*dp2*v

where H is the plate height, L is the length of the column, dp is the diameter of the
packing material, v is the linear velocity of the mobile phase, and A, B, C are constants.
Since values of A, B, and C are dependent on column/packing material/analyte
characteristics it is not possible to establish the exact quantitative relationship between a
change in dp and N. However, it can be reasonably assumed that the B term is negligible,
because it is only at impractically slow mobile phase linear velocities that this term is
significant. Thus the relationship between dp and N is inversely proportional ranging
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from dp and dp2. As particle size is decreased, efficiency increases, and greater resolution is
achieved.

3.4.2 Discussion of effect of number of buffer components on peak width

The displacement mechanism of ampolyte displacement chromatography [4,5]
proposes the formation of a pH gradient within the column through a gradient distribution
of different acidic ampholytes with in the anion exchange column, with the proportion of
stronger to weaker acidic components gradually decreasing down the length of the
column. In this mechanism more acidic components successively move down the column
displacing less acidic components continuously lowering the pH of the column. This
displacement process displaces the proteins down the column through successive pH
bands of ampholytes that have the same affinity for the ion-exchanger sites as the protein.
These pH bands push one another down the column at the same rate.

If the elution buffer has a greater number of buffer components, protein passes
through stronger/more acidic pH zones which push and force them displaces completely
from the anionic sites of the ion-exchanger. As a result, the pH bands of ampoholyte
become narrower (spreading of these pH bands decreases) thus the proteins which are in
that narrower pH bands are focused into narrow bands and will have smaller peak widths.
As more elution buffer enters the column, additional stronger acid components displace
the weaker acid components, and these weaker components displace even weaker acid
substances downstream to it.
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One can propose similar mechanism for movement of buffer component in
gradient chromatofocusing, with the stronger buffer components displacing weaker buffer
components. Thus with more buffer components in the mobile phase having closer pKas
the proteins will travel in the bands that match their pI and since the pH bands are
narrower the proteins themselves will elute in narrower bands.

3.5. Development of multi buffer component system for generating linear pH
gradients to separate multiple forms of prolactin having closely related pI values

3.5.1. Background

Prolactin (PRL) is a protein hormone and regulates the mammary gland and
reproductive system. Besides these its best known physiological actions, more than 300
different and distinct actions of PRL have been reported which include effects on growth
and development, osmoregulation and behavior, endocrinology and metabolism, brain
and behavior, immune regulation and protection [6]. Studies have been reported that this
broad versatility in biological activities of prolactin is due to its structural polymorphism
which exists in several molecular sizes. The analysis of prolactin in animals was analyzed
by different methods like electrophoresis, RIAs, bioassay, chromatography of plasma and
pituitary extracts revealed that the hormone is existed in more than one form [7].
Fractionation by size exclusion chromatography of PRL from male rat pituitaries and
plasma showed the size heterogeneity of this protein hormone ranging from 30.4, 27.1,
25.6, 24.3,23.6, 21.5KD and the chromatofocusing of pituitary PRL predominant size
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variant 24.3KD exhibited the charge variants of pI 5.34, 5.31, 5.26, 5.20 and 5.14[8].
Three differently charge isoforms of rat prolactin was isolated by molecular sieve
chromatography on Sephadex G-100 and column electrophoresis in agarose suspension
as well as the electrophoresis resolved prolactin activity into three to four immune active
components have been reported[9]. Studies have been reported that the arising
heterogeneity in molecular size variants related to genetic and posttranslational events in
pituitary cells as well as metabolic process like glycosylation and proteolysis [8, 9]. A
size-exclusion HPLC method was developed to separate the three different prolactin
forms: monomeric prolactin (~23 KDa), big prolactin (~60 KDa), and macro prolactin
(~150 KDa) [10].

The present work utilizes anion-exchange gradient chromatofocusing method,
optimizing the separation of the multiple forms of the enzymes and proteins by focusing
into narrow bands.

3.5.2. Experimental

3.5.2.1. Materials and injected samples

HEPES (catlog no. H3375), BES (catlog no.B9879) , PIPES (catlog no.P6757 ) , bis-tris
methane (catalog no. A0293971) from Fisher (New Jersey, USA), 2-methyl
benzimidazole (catlog no.65840), 4-methyl pyridine(catlog no. 239615, 3-methyl
pyridine (catlog no. 42053), isoquinoline (catlog no. I28208), pyridine (catlog no.
270970), trimethyl aceticacid (catlog no. T71803), acetic acid (catlog no. H3375), 482

chlorobutanoic acid (catlog no.C29835), 4-chloropenyl acetic acid (catalog no. 695092),
lactic acid (catalog no. 252476), ammonium bicarbonate (catalog no. A6141), prolactin
from sheep pituitary (L6520) were purchased from Sigma-Aldrich (St.Louis, MO). A
poly weak anion exchange column (50 x 2.1 mm, 3µ, 300 Å) was purchased from The
Nest Group (Columbia, MD, USA). Protein sample prepared in DI water. 50 µL of 100
uM prolactin was injected

Mass spectrometric materials for infusion experiments of eluted prolactin isoform
peaks were acetonitrile (catalog no.34967), formic acid (catalog no. F0507), methanol
(catalog no. 14262) from Sigma (St.Louis, MO). The ultra mciro C4 spin column for
desalting (p/n: SUM SS04V) was purchased from The Nest group (Columbia, MD)

3.5.2.2. Chromatographic conditions

PEI weak anion- exchange column (50 X 2.1 mm, 3µ, 300Å) was purchased from
The Nest group (Columbia, MD 21045, USA). The flow rate was 0.2 mL/ min.
Chromatographic conditions are the same as indicated in section 3.2.2.

3.5.2.2.1 Thirteen component buffer system

A thirteen component buffer system was developed to generate a linear shallow pH
gradient that consisted of multiple buffer components with evenly spaced pKa values
approximately 0.25. In this buffer system, application mobile phase A (high pH buffer)
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consisted of 10 mM of each HEPES (7.4), BES (7.09), PIPES (6.76), bis-tris methane
(6.5), 2-methyl benzimidazole (6.19), 4-methyl pyridine(6.02), 2-ethyl pyridine(5.89),3methyl pyridine(5.68), isoquinoline (5.42), and pyridine (5.25). Elution buffer B (low pH
buffer) composed of 10 mM of each trimethyl acetic acid (5.03), acetic acid (4.76), 4chlorobutanoic acid (4.52), 4-chlorophenyl acetic acid (4.19), and lactic acid (3.81). The
pKa values for the buffer components are given in parentheses.

3.5.2.2.2. Six component buffer system with NaCl

Application buffer compsed of 10mM of each ammonium bicarbonate, bis-tris methane,
3-methyl pyridine, and 5mM of acetic acid. Elution buffer consisting of 10 mM of each
acetic acid, lactic acid, chloroacetic acid, 5 mM of 3-Methyl pyridine, and 25mM of
NaCl.

3.5.2.3. Mass spectrometric infusion experiments of eluted prolactin isoform peaks

After injecting the prolactin (50uL of 100uM) on PEI weak anion-exchange
column, the fractions were collected for each separated isoform of prolactin immediately
after the detector at their retention times when it eluted. Five fractions were collected for
five forms and were infused on mass spectrometer for molecular weight determination.
Since each form of prolactin fraction eluted with buffer components, the fractions were
desalted to remove all buffers before infusing on mass spectrometer. The ultra micro spin
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C4 column was used for desalting of all collected fractions of prolactin forms. These
columns will retain non-polar solutes such as peptides, proteins, and detergents. Salts,
buffers and polar solutes will not be retained.

Initially the column was conditioned by pipetting 200uL of 100% methanol into
the column to soak the column bed in it. Then the column was equilibrated two times
with 200uL of 0.1% formic acid in deionized water. 100uL of prolactin fraction was
injected onto the column and washed the column twice with the 200uL of 0.1% formic
acid in DI water. This will enable the protein to bind the column and flush out/ remove all
the salts from the samples as well as from the column. The sample was then eluted using
200uL of 0.1% formic acid in 60% acetonitrile. The eluted protein isoform samples were
speed vac dried and reconstituted in 0.1% formic acid in 60% acetonitrile for mass
spectrometry infusion analysis.
Infusion experiments were carried out for desalted fraction samples using a Brukers’s
Esquire HCT ion trap mass spectrometer (Billerica, Massachusetts, USA) equipped with
electro spray ionization (ESI) in positive mode to determine the, molecular mass of each
from of prolactin. The mass spectrometer parameters were as follows: The scan range is
100-2800 m/z; nebulizer gas at 15 psi; drying gas flow is 10L/min; drying temperature is
320 oC. The maximum accumulation time was 2 ms and the infusion rate was 10uL/min.
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3.5.3. Results

3.5.3.1 GCF of prolactin isoforms with thirteen buffer component system

A linear pH gradient ranging pH from 6 to 2.5 was generated on the PEI weak anion
exchange column with a simple 0%B-100% B in 35 minutes gradient program utilizing
the application and elution mobile phases described in section 3.5.2.2 with the resulting
gradient given in Figure 3.5.

The bridging design discussed in chapter 2 was not required for generating a smooth
linear pH gradient with the thirteen component buffer system. The reason behind this was
the buffer components were chosen with pKa values evenly spaced apart by
approximately 0.25 pH units over the range (6 to 2.5) of the pH gradient. The difference
in spacing was much less for this new buffer system compared to buffer system IB and
buffer system IIB. This smaller spacing of pKa values between buffer components
provided high even buffering capacity necessary for generating smooth pH gradients
throughout the desired pH range. The resulted linear pH gradient can be seen in Figure
3.5.
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Figure 3.5. Linear pH gradient generation with thirteen buffer component buffer
system on PEI weak anion-exchange column with a simple 0-100%B in 35 min
linear gradient program.
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After producing the desired slope pH-gradient using this new buffer system, the
generated gradient was employed to resolve the different variants having closely related
pI values of commercial prolactin (from sheep pituitary) isoforms. Prolactin was injected
on the PEI weak anion exchange column, however no prolactin peaks eluted from the
column. Attempts were made to elute the prolactin by increasing the concentration of
elution buffer from 10mM to 25mM and adding 25mM of NaCl in elution buffer did not
solve the problem. The reason might be the protein was denatured or precipitated as it
was exposed to more organic environment.

3.5.3.2 GCF of prolactin isoforms with six buffer component buffer system

The irreversible adsorption problem was solved by using six component buffer
systemwith NaCl which resolved the prolactin variant isoforms. The buffer components
are given in Table 3.3. One buffer component was introduced in application buffer and
25mM of sodium chloride was added to elution buffer in order to increase the ionic
strength. The bridging technique was utilized for this buffer system to generate the linear
pH gradient for the separation of prolactin isoforms.

The linear pH gradients without and with the bridging buffer components are plotted in
Figures 3.6 and 3.7, respectively. The resulting GCF chromatogram of the prolactin
isoforms using the six component buffer system with NaCl and with bridging buffer
components is given in Figure 3.8, showing excellent resolution of the five prolactin
isoforms.
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Table 3.5. Six component buffer with bridging components and NaCl

Basic application
buffer (each
component 10mM)
Ammonium
bicarbonate
(9.26)
Bis-Tris
(6.5)

3-Methyl
(5.68)

Acidic elution
buffer (each
component
10mM)
Acetic acid (4.76)

methane

Lactic acid (3.81)

pyridine

Chloroacetic acid
(2.)

5mM of acetic acid

5mM of 3-methyl
pyridine

25 mM Sodium
chloride
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Figure 3.6. The pH gradient generated with six component buffer system with NaCl
without bridging with 0 -100%B in 35 mins linear time gradient program
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Figure 3.7. The pH gradient generated with six component buffer system with NaCl
with bridging with 0 -100%B in 35 mins linear time gradient program
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Figure 3.8. GCF separation of different isoforms of prolactin on PEI weak anionexchange column using pH linear gradient of Figure 3.7.
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Peak widths at half height, pI values of prolactin isoforms according to literature,
and the elution pH are given in the Table 3.4. Resolution of adjacent eluting peaks of the
prolactin isoforms was calculated from retention times and peak widths at half heights
and given in Table 3.5.
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Table 3.6. Peak widths at half height, literature pI and elution pH of isoforms of
prolactin

Prolactin
isoforms

Peak widths at half
height (min)

Literature pI
values of
prolactin
isoforms

Elution pH
of prolactin
isoforms

Isoform 1

0.52

5.34

5.81

Isoform 2

0.68

5.31

5.75

Isoform 3

0.47

5.26

5.35

Isoform 4

0.73

5.20

5.12

Isoform 5

0.28

5.14

4.94
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Table 3.7. Resolution of adjacent eluting prolactin isoforms

Prolactin isoform pair

Resolution (RS)

Isoforms 1& 2

4.16

Isoforms 2& 3

9.69

Isoforms 3 & 4

1.24

Isoforms 4& 5

1.37
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3.6. Molecular mass determination of prolactin variants

Studies reported that the prolactin shows the size heterogeneity and exists in
several molecular sizes ranging from 30.4 KD to 21 KD [3]. So infusion experiments
were carried out to determine the molecular masses of pI based isolated multiple forms
prolactin.

3.6.1. Results

Prolactin harmone exhibits size heterogeneity ranging from 30 kDa to 21.5 kDa (30.4,
27.1, 25.6, 24.3, 23.6, 21.5 kDa) according to published literature. The deconvoluted
mass spectrums of five fractions of prolactin forms gave the molecular masses of 21.5,
27.3, 26.1, 21.5, 26.9 kDa respectively. The molecular masses of the five peaks are
within the molecular mass range for prolactin, giving supporting evidence that the peaks
are likely prolactin peaks. The infusion mass spectrums of five fractions of prolactin
isoforms and corresponding molar masses of each fracion are shown in Figures 3.9 –
3.13.
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Figure 3.9. The infusion mass spectrum of isoform 1
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Figure 3.10. The infusion mass spectrum of isoform 2
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Figure 3.11. The infusion mass spectrum of isoform 3
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Figure 3.12. The infusion mass spectrum of isoform 4
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Figure 3.13. The infusion mass spectrum of isoform 5
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CHAPTER IV

Bioanalytical Methods and Applications

4.1. Introduction

Bioanalytical methods developed for the accurate quantification of drugs and their
metabolites in biological samples are the key parameters in producing accurate and
reproducible data which in turn are utilized in the assessment and interpretation of
pharmacokinetics, bioequivalence, bioavailability, and toxicokinetics findings. This plays
a vital role in understanding diseases, clinical diagnosis, and drug discovery and
development [1]. It is known that bioanalytical methods and technologies are continually
changing and improving significantly to yield reliable results which can be analyzed
accurately. This facilitates to develop well characterized and fully validated analytical
methods. In the last decade there have been remarkable advancements in bioanalysis
technologies, which fulfill the requirements of clinical and pharmaceutical fields,
especially in the field of mass spectrometry with the development of new interfaces,
ionization, and detection techniques[2]. Due to its more rapid throughput and increased
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sensitivity, hyphenated mass spectrometry (LC-MS-MS) based assays significantly
replaced the conventional HPLC-UV, GC and other bioanalytical techniques[3, 4].

Major advances in the field of drug discovery and development aided increase in the
number of new drug targets. However, the number of new drug approvals has not kept
pace with the increased cost of their development. Increasingly, innovative uses of
biomarkers are employed in an attempt to speed new drugs to market [5, 6]. Biomarkers
are increasingly used in drug development to improve the understanding of disease as
well as therapeutic effects of drugs contributing to improving the patient care. The
biomarkers are used in monitoring the different biological entities including proteins,
nucleic acids and metabolites to reflect the

disease progression and therapeutic

progression [Biomarker (medicine) wiki]. Presence of biomarkers often in low amounts
in biological samples, diverse nature of biomarker analysis and its wide range
applications in drug development bringing grate challenges in

obtaining reliable

detection and validation. So there is a need to develop a standardized method and
validation guidelines to measure the biomarkers [7].

Apart from wide range of bioanalytical applications in biomarker detection, the
development

of quantitative bioanalysis

has

significantly been

increased in

pharmaceutical drug discovery and development[3]. Quantitative bioanalysis provides the
information to understand the pharmacological properties including absorption,
distribution, metabolism and elimination (ADME), as well as toxicity to guide the drug
screening for lead compounds.
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4.1.1. Bioanalysis applications in drug discovery and development

In the process of drug discovery evolution, pharmacokinetics, toxicity and preclinical
drug metabolism studies play crucial role in identification and optimization of lead
compounds. An ideal drug candidate should exhibit the ability be absorbed in blood
stream, reach desirable concentration for effective activity, and be excreted without
producing toxic metabolites. Knowledge and understanding of pharmacokinetic and
metabolism characteristics of the lead compounds is required in drug discovery [8].
Different stages of drug development process are shown in Figure 4.1.
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Figure 4.1. Various stages of drug discovery
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Pharmacokinetic (PK) studies provide a mathematical basis to evaluate the time course of
drugs and their effects in the body. PK describes how the body affects a specific drug
after administration through the absorption, distribution, metabolism, and excretion
processes. These pharmacokinetic processes usually referred to as ADME, determine the
drug concentration in the body when the drug is administered. PK enables the ADME
mechanisms to be quantified [9] .

Absorption is the process that the drug entering the blood stream circulation after
administration of it by any route. The process of dispersion of a drug rapidly from blood
to throughout the fluids and various tissues of the body is called distribution. A drug is
excreted directly through an excretory route like urine, bile etc. from the body which is
known as elimination. The drug eliminated indirectly via enzymatic and biochemical
transformation by the liver as is called metabolism. Metabolism is the elimination of
foreign and undesirable compounds from the body. It is also known as detoxication . The
drug path from the blood is represented in Figure 4.2. Pharmacokinetic data is very useful
in optimization of the dosage form design and establish the dosage interval [10, 11].
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Figure 4.2. Schematic diagram of ADME process of a drug
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The rates of ADME process can be characterized by zero-order reaction and first
order reaction. In zero-order reaction, considering if the amount of drug A is decreased at
a constant rate and then the rate of elimination of A is:
dA/dt = ‒k* (k*= zero-order rate constant)

The rate of elimination of the drug is independent of the concentration of the drug
present in the body. In the first-order reaction, the elimination rate of drug A decreases as
the drug A concentration decreases in the body[12]. This relationship is
dA/dt= ‒kA (k= first-order rate constant)

Elimination of the most of the drugs at therapeutic dosages generally follows the
first-order kinetics. Common measurements and important parameters used in PK (Figure
4.3) analysis are C max (the maximum concentration recorded), Tmax (the time taken to
reach C max), AUC (area under the curve ‒ a measure of the exposure to the drug), and t1/2
(elimination half-life ‒ the time taken for the plasma concentration to fall by half its
original value) [11-13].
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Figure 4.3. Common measurements used in PK analysis
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High-throughput screening in-vitro ADME assays have been implemented in
early drug discovery to study the drug-drug interaction and to identify and eliminate the
compounds with poor drug properties as well as to promote potential drug candidates for
in-vivo pharmacokinetic profiling [13-15]. However, in-vitro ADME assay results cannot
truly represent the real physiological environment and always cannot asses the in-vivo PK
parameters properly. In spite of many advances in in-vitro technologies, these approaches
are not always reliable and accurate which may lead to mistaken conclusion about drug
metabolism [16, 17]. The PK profile of a compound is controlled by many
physicochemical and chemical properties of the molecule such as lipophilicity, solubility,
permeability and metabolic stability. The in- vivo ADME processes through an intact
animal or human are frequently far more complex than in isolated in -vitro systems.
Therefore it is necessary to have in-vivo testing and confirmations of in-vitro ADME
results in early drug discovery to improve the candidate selection through animal models
[18, 19].

In order to predict the drug behaviors in-vivo and in-vitro accurately, there is
always a continuous demand for bioanalytical method’s support in pharmaceutical
industries. These bioanalytical methods are essential to construct a concentration-time
profile. The techniques are used to measure the concentration of drug in biological fluids
or matrix, most often plasma, serum, and urine. So proper bionalytical methods employed
for the quantification should be selective and
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sensitive. These requirements can be accomplished by advanced chromatographic and
mass spectrometric techniques and accurate sampling procedures. LC-MS based methods
have become widely accepted as an integral part of the drug discovery and
development[3].

4.2. Quantitative LC-MS/MS analysis for small molecules and pharmaceutical
analysis

Recent bioanalytical technologies have been considerably expanded over the past
decade for quantitative determination of small molecules and large molecules in
biological

samples

accurately.

The

combination

of

high-performance

liquid

chromatography (HPLC) with tandem mass spectrometry (MS/MS) detection is
considered as the preferred method for the quantitative determination of drugs and
metabolites in biological fluids due to its high sensitivity, selectivity, and short analysis
time [2, 20, 21]. In pharmaceutical analysis, the hyphenated LC-MS is the most powerful
technique because of the complex nature of the matrix (often plasma or urine) and the
need for high sensitivity to observe concentrations after a low dose and a long time
period [2, 3].

The most common instrumentation used in this application is LC-MS with a triple
quadrupole mass spectrometer with ESI or APCI interface. Tandem mass spectrometry is
usually employed for added specificity[2].
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4.2.1. MS detection

General mechanism of MS detection is the analyte in liquid flow from the HPLC
goes into three components of mass spectrometer of ionization source in which the
sample is ionized, mass analyzer in which the ions are separated and sorted according to
their mass and charge ratio, and the detector which measures and detects the separated
ions. The mass spectrometry is capable of not only indicating the presence of impurities
but also able to give the molecular weights of underlying components and to distinguish
between different molecules.

HPLC/MS became a success with the introduction of atmospheric pressure
ionization (API) ten years back which enables the MS analysis by generating ions in a
stream of liquid after HPLC separation. The most widespread method for quantifying
small molecules is quadrupole MS interfaced with a number of API sources such as
electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI) .These
ionization sources convert the sample from liquid phase to gaseous state [2].

In electrospray ionization, the analyte is introduced to the ion source in solution
either from a syringe pump or as the eluent flow from liquid chromatography. The
analyte solution flow passes through the electrospray needle that has a high potential
difference (with respect to the counter electrode) applied to it (typically in the range from
2.5 to 4 kV). This forces the spraying of highly charged fine droplets from the needle
with a surface charge of the same polarity to the charge on the needle. After solvent is
further evaporated from these droplets, the droplet shrinks until it reaches the point that
the surface tension can no longer sustain the charge at which point a coulombic explosion
114

occurs and the droplet is diffused apart leaving the ions to enter to the mass analyzer. The
process of ESI is shown in Figure 4.4.

115

Figure 4.4. The schematic diagram of ESI source
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Unlike ESI, APCI evaporates the solvent by passing it trough a heated tube where
the high voltage is applied to needle to generate a corona discharge and forming the
plasma ions in the solvent. These solvent ions ionize the analyte molecules by means of
gas phase reactions[2].

Mass analyzers separate the ions according to their charge to mass ratio (m/z) by
accelerating the ions with applying electric or magnetic field. Based on mass range limit,
analysis speed, mass accuracy, and resolution, there are different types of mass analyzers
are used. These include quadrupole MS, ion-trap MS, and time of flight (TOF) MS.

The quadrupole mass analyzer (Figure 4.5) uses an electric field to select and separate the
ions with a particular m/z. It consists of four parallel metal rods where adjacent rods have
opposite voltage polarity applied to them. The voltage applied to each rod is the
summation of a constant DC voltage and a varying radio frequency.
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The electric force on the ions causes the ions to travel down the quadrupole
between the rods. Only ions of a certain mass-to-charge ratio will reach the detector for a
given ratio of voltages. Quadrupole analyzers have a limited m/z range, high sensitivity
and mass accuracy, but low percentage of ion transmission. Triple quadrupole (QqQ)
mass analyzer consists of three quadrupoles arranged in a linear series. Precursor ions
filtered in the first quadrupole (Q1) are dissociated in the collision cell (q2) in the
presence of inert gas such as Ar, He or N2 gas, and resulting selected fragments are
filtered or scanned by third qudrupole (Q3) achieving high specificity.

The quadrupole ion-trap mass analyzer employs similar principles as the quadrupole
analyzer mentioned above, it uses an electric and magnetic fields for the separation of the
ions by mass to charge ratios. The ion-trap MS (Figure 4.6) has the advantage of its high
sensitivity and resolution.Time-of-flight (TOF) mass spectrometers use an electric field
to accelerate gas phase ions toward a detector. The m/z of an ion will determine how long
it takes for it to travel from the source to the detector, with low m/z ions traveling faster
relative to high m/z ions. Several designs of TOF analyzers exist, some using a linear
flight tube and others using 1 or more reflectrons that change the direction of ion flight
and improve resolution or the ability to distinguish two m/z ratios from one another. TOF
analyzers have an essentially unlimited m/z range and very high sensitivity, mass
accuracy, and percentage of ion transmission, but a limited dynamic range. The modern
MS instrument hybridizes different types of mass analyzers on one instrument to broaden
the tandem mass spectrometry applications.
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Figure 4.5. The operation of quadrupole mass analyzer
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Figure 4.6. A schematic way of a ion-trap mass analyzer
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The mass spectrometric detection of target analyte ions employ selected ion
monitoring (SIM) and multiple reaction monitoring (MRM) scanning modes for LC-MS
and LC-MS/MS methods respectively. The SIM mode detection allows to select the
desired m/z value for the target analyte by the instrument. This mode of analysis requires
a single quadrupole and only the m/z of a precursor ion because no fragmentation is
induced. Because only a limited mass-to-charge ratio range is transmitted or detected by
the instrument, this operation typically results in significantly increased sensitivity.

Comparing with SIM, MRM mode detection provides the unparalleled specificity
because this analysis utilizes triple quadrupole mass analyzer to select and analyze a
specific analyte. In MRM mode, two stages of mass filtering are employed on a triple
quadrupole mass spectrometer. In the first stage, an ion of interest (the precursor) is
preselected in Q1 and induced to fragment by collisional excitation with a neutral gas in a
pressurized collision cell (q2). In the second stage, instead of obtaining full scan ms/ms
where all the possible fragment ions derived from the precursor are mass analyzed in Q3,
only a small number of sequence-specific fragment ions (transition ions) are mass
analyzed in Q3. This targeted MS analysis using MRM enhances the lower detection
limit as compared to full scan ms/ms analysis by allowing rapid and continuous
monitoring of the specific ions of interest. Particular precursor ions and product ions are
selected for detection based on their unique pathways, MRM provides a great
improvement in signal to noise ratio.
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4.2.2. HPLC separation

Liquid chromatography is the basic separation technique for the separation of
analyte of interest from the components of mixture. High-performance liquid
chromatography (HPLC) is the most widely used separation method in bioanalysis. The
mechanisms of liquid chromatography are based on distribution and partition of analyte
between liquid mobile phase and stationary phase. There are different types of
chromatographic methods based on different types of stationary phases applied. These
include ion-exchange chromatography (IEC), reversed-phase chromatography (RPLC),
normal phase chromatography (NPLC), and size-exclusion chromatography (SEC) etc.

Besides traditional HPLC, there are some modern approaches such as ultraperformance chromatography and hydrophilic interaction chromatography (HILIC) to
improve the chromatographic separation efficiency and resolution. By using smaller
particles, speed and peak capacity can be extended to new limits, termed Ultra
Performance Liquid Chromatography (UPLC). This technique takes full advantage of
chromatographic principles for separations using columns packed with smaller particles
and higher flow rates for increased speed, with superior resolution and sensitivity over
conventional HPLC by handling elevated pressure.
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All small molecule compounds and peptides are separated by RP-LC with a C18
column and mass spectrometric detection. A guard column is used to prevent the
contamination from the injected biological samples and damage from the mobile phase
additives. A successful quantitative LC-MS/MS method development requires three
important interlinked methodologies: MS detection, chromatographic separation and
sample preparation. The steps involve in general method development process shown in
Figure 4.6.

Several types of sample preparation methods are existed to extract the analyte
from the biological matrices such as solid phase extraction (SPE), liquid-liquid extraction
(LLE), and protein precipitation (PP).
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Obtain the chemical structure
and properties of compound

Develop MS detection

Develop separation method

Develop sample extraction
method

Test method for interference
and validation

Figure 4.7. Method development workflow for small molecules
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4.3. Development and validation a LC-MS/MS method for determination of voltagegated calcium channel and NMDA receptor antagonist NGP1-01 in mouse serum

4.3.1. Abstract

NGP1-01 (8-benzylamino-8, 11-oxapentacyclo [5.4.0.02, 6.03, 10.05, 9]
undecane) is a heterocyclic cage compound with multifunctional calcium channel
blocking activity that has been demonstrated to be neuroprotective in several
neurodegenerative models. The primary mechanism of neuroprotection is through the
blocking of the N-methyl-D-aspartate receptor (NMDA) and the L-type voltage-gated
calcium channel to modulate excessive calcium influx into neurons. A sensitive internal
standard LC-MS/MS method was developed and validated to quantify NGP1-01 in
mouse serum. The internal standard was 8-phenylethyl-8, 11-oxapentacyclo [5.4.0.0(2,
6).0(3, 10).0(5, 9)] undecane. Sample preparation involved a protein precipitation
procedure by addition of acetonitrile. Chromatographic separation was carried out on a
Phenomenex Kinetex phenyl-hexyl column (100 x 2.1 mm, 2.6 μm) employing a linear
gradient (45% to 95% in 6 min) of 5mM ammonium acetate in 2% acetonitrile mixing
with increasing proportions of 5mm ammonium acetate in 100% acetonitrile. Detection
was achieved by QTrap 5500 mass spectrometer (AB Sciex) employing electrospray
ionization in the positive mode. Multiple-reaction-monitoring (MRM) was employed for
NGP1-01 (m/z 266 → 91) and for the internal standard (m/z 280 → 105). The method
validation was carried out in accordance with Food and Drug Administration (FDA)
guidelines. The method had a linear range of at least 0.5–50 ng/mL with a correlation
coefficient 0.999. The intra-assay and inter-assay precisions (%CV) ranged from 1.0 to
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4.3% and accuracies (% relative error) ranged from -2.5% to 3.4%. The analyte was
stable for at least 2 months at -20⁰ C, for at least 10 hours at room temperature and for at
least three freeze thaw cycles. The absolute recovery was 99 to 102% with a %CV ≤
4.5%. The optimized method was applied in the measure of NGP1-01 in serum, brain and
retinal samples from dosed mice.

4.3.2. Introduction

An increasingly important focus in drug discovery research in recent years is
development of multifunctional drugs, agents with more than one therapeutic mechanism.
Various terminologies besides multifunctional has been used in the literature for this
category of drugs that is based on multiple therapeutic effects, including: designed
multiple ligand, dual mechanism, dual ligand, bifunctional, multimechanistic,
multimodal, pan agonist, and hybrid drugs. Two extensive reviews of the literature on
the development and use of multifunctional drugs applied to various diseases have been
published [22, 23]. Significant advantages of multifunctional drugs over conventional
drugs that target one protein include: 1) many diseases have multi-factorial pathology
and 2) there is a reduced likelihood of multifunctional drugs developing resistance [24].
Use of multifunctional drugs is also considered a better therapeutic strategy compared to
use of multiple drugs (polypharmacy) to treat multi-factorial pathology due to the
inherent complexities in polypharmacy approaches resulting from different degrees of
bioavailability, pharmacokinetics and metabolism of the different drugs [25, 26]. In
addition, the drug-drug interactions that often occur in the polypharmacy regimen, leads
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to a combined, or even multiplied, toxicity that is not inherent in a multifunctional drug
[27].

One area in which multifunctional drugs can potentially make a significant impact
is neurodegenerative diseases, many of which have been shown to have multi-factorial
pathoetiological effects and origins [28, 29]. Multiple etiologies in neurological diseases
are indicated from multifunctional drug studies [29-31] including: anti-amyloid, anticholinesterase and anti-oxidant activity in Alzheimer’s disease [32, 33]; anticholinesterase and monoamine oxidase-B (MAO-B) inhibitor activity in Alzheimer’s
disease, Parkinson’s disease and Lewy body disease [34, 35]; iron chelator and MAO-B
inhibitor activity in Alzheimer’s disease [24] ; adenosine A2A receptor and MAOinhibitory activity in Parkinson’s disease [36] ; and pertinent to the present work, dual
mechanism of modulating calcium entry in neuronal cells via L-type calcium channels
and N-methyl-D-aspartate (NMDA) receptors important for its neuroprotective action in
Alzheimer’s, stroke and other neurodegenerative diseases [37]. In addition to the above,
there are multiple etiologies in Huntington disease, amyotrophic lateral sclerosis,
schizophrenia, depressive illness and stroke, Glaucoma and other eye diseases [29].

A deficiency in current therapies in neurodegenerative diseases is neuroprotection
activity to prevent further loss of neurons. Thus, recent investigations have sought to
develop neuroprotective agents to treat chronic neurodegnerative disorders such as
Parkinson’s and Huntington’s diseases [19]. Excessive influx of calcium into neuronal
cells resulting in cell death (a pathological process known as excitotoxicity) has been
implicated in continuous and irreversible loss of neurons from the central nervous system
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and certain regions of the brain leading to neurodegeneration [38-41]. Thus proteins
controlling calcium influxes into neuronal cells are potential drug targets for developing
the neuroprotective agents.

A promising multifunctional agent which has shown neuroprotection in
neurodegenerative disease systems is NGP1-01, the pentacycloundecylamine 8benzylamino-8, 11-oxapentacyclo [5.4.0.02, 6.03, 10.05, 9] undecane. NGP1-01 (Figure
4.8A) is a heterocyclic cage compound first characterized by Van der Schyf group in the
mid 1980s [42] . NGP1-01 has been shown to produce neuroprotective effects by
inhibiting calcium uptake by acting as an uncompetitive antagonist of both the ligandoperated calcium channel (NMDA receptors) and the voltage-gated calcium channels
(VGCC) in neuronal cells [42-45], thus preventing the increased intracellular calcium
excitotoxicity effect leading to neuronal cell death by necrotic or apoptotic mechanisms
[46-48] .

NGP1-01 and derivatives of NGP1-01 have also been shown to have other
functional effects pertinent to neurodegenerative diseases, in addition to the
aforementioned inhibition effect on calcium uptake by neuronal cells. First, it has also
been shown that VGCCs provide an alternate route for iron uptake by neuronal cells
which contributes to neuronal cell toxicity and death [49]. NGP1-01 was found to reduce
iron uptake in brain endothelial cells via the VGCC route [50]. Second, NGP1-01 and its
derivative afforded neuroprotection by a presumed blocking of the dopamine transporter
in the 1-methyl-4-phenyl-1, 23, 6-tetrahydropyridine (MPTP) Parkinsonian mouse model
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[41, 51]. Third, NGP1-01 was found to exhibit considerable neuroprotection in a mouse
middle cerebral artery occlusion model after transient focal brain ischemia [52].

Thus NGP1-01 is a promising therapeutic candidate for treatment of
neurodegenerative disorders through its multimodal effects. Development of sensitive
analytical methodology for its determination in biological samples is warranted. The only
reported analytical method for the determination of NGP1-01 is a HPLC technique
employing UV absorbance detection at 210 nm, which was applied to the compound in
aqueous solutions studying compound stability [53, 54] This technique is not applicable
to biological samples because of a poor limit of detection and low analytical specificity
inherent in absorbance detection. Although these studies also developed a LC-MS
technique for NGP1-01, it employed out-of date particle beam ionization technology and
it was not used analytically, being used solely for mass spectral identification of the
HPLC peaks.

The present work reports the development and validation of a sensitive and
specific LC-MS/MS technique for NGP1-01, applied to the determination of NGP1-01 in
mouse serum, brain and retinal tissues.
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4.3.3. Experimental

4.3.3.1. Chemicals and Materials

NGP1-01 (Figure 4.8A) and the internal standard (IS), 8-phenylethyl-8, 11oxapentacyclo [5.4.0.0(2, 6).0(3, 10).0(5, 9)] undecane (phenyl-ethyl-NGP1-01) (Figure
4.8B), were synthesized and purified [42, 51]. HPLC grade dimethyl sulfoxide (DMSO)
and Optima LC/MS grade acetonitrile (ACN) were from Fisher Scientific (Fair Lawn, NJ,
USA). ACS reagent grade ammonium acetate was from Sigma-Aldrich (St.Louis, MO,
USA). HPLC grade water was from a Barnstead NANO pure water purification system
with a Nanopure Diamond Pack Organic Free cartridge from Thermo Scientific (West
Palm Beach, FL, USA). Mobile phases were filtered through 0.45µ membrane filters
from Millipore (Billerica, MA, USA). Homogenizing apparatus was from Kontes Glass
(Vineland, NJ, USA). Six individual lots of mouse serum (Non Swiss Albino) were from
Innovative Research (Novi, MI, USA). Dosed serum, brain, and retina samples were from
four different mice. Animal procedures were carried out according to the procedure
approved by the Animal Care and Use Committee (IACUC) at Northeast Ohio Medical
University.
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Figure 4.8. The chemical structures of NGP1-01 (A) and the IS, phenyl-ethyl-NGP101(B)
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4.3.3.2. Stock and working DMSO solutions

Stock solutions of NGP1-01 and phenyl-ethyl-NGP1-01 (IS) were prepared at a
concentration of 1mg/mL in DMSO. Serial dilutions of NGP1-01 stock solution with
DMSO gave the corresponding working DMSO solutions at concentrations of 10, 20, 40,
100, 200, 400, and 1000 ng/mL. In the same manner, NGP1-01 quality control (QC)
working DMSO solutions were prepared with DMSO at concentrations of 24, 140, and
800 ng/mL. The internal standard (IS) working solution at 100 ng/mL was prepared by
dilution of IS stock solution with DMSO. All stock and working solutions were stored at
-20⁰ C in amber glass vials.

4.3.3.3. Preparation of calibration and quality control working serum solutions

Calibrator and QC working serum solutions were prepared using six lots of
pooled commercial mouse serum as diluent. The calibrator working serum solutions at
0.5, 1, 2, 5, 10, 20, and 50 ng/mL were prepared by spiking 10µL of the corresponding
NGP1-01 working DMSO solutions into 200 µL of pooled mouse serum. QC working
serum solutions at 1.2 (low), 7.0 (mid) and 40 (high) ng/mL were prepared by addition of
10µL of the corresponding NGP1-01 working DMSO solutions to 200 µL of pooled
serum. The calibrator and QC working serum solutions were vortexed for 20 sec, and
then stored at -20⁰ C before sample preparation and the LC-MS/MS analysis described
below.
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4.3.3.4. Preparation and storage of dosed samples

Dosed serum, brain and retinal samples were stored at -20⁰ C until sample
preparation steps were done as described below. A portion of the dosed mice brain was
weighed and homogenized with twofold amount of phosphate buffered saline (PBS) (e.g.
100 mg brain / 200 μL PBS) for two minutes using the homogenizing apparatus. In the
same manner, each dosed mouse retina was weighed and twofold amount of PBS was
added and homogenized. These prepared brain and retinal samples were processed as
described in section 2.5.

4.3.3.5. Preparation of calibrator standards, QC standards, blanks and dosed
samples for analysis

The calibrator and QC working serum solutions and the dosed serum samples
were thawed to room temperature and taken through the preparation steps (as were the
prepared brain and retinal samples), as given below. A volume of 10 µL of IS work
solution was added to 200 μL of each sample to give a final IS concentration of 5 ng/mL.
Double blanks were prepared by adding 20 μL of ACN to 200 μL of pooled commercial
serum without adding the analyte and IS, where as single blanks were prepared by
spiking 10 μL of IS work solution and 10 μL of ACN into 200 μL pooled serum. Next, a
protein precipitation step was done to all samples as follows. After a 20 seconds vortex,
800 μL of ACN was added to each of the sample which were then sonicated for 10
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minutes and centrifuged at 13,000 g for 20 minutes. The supernatants were then pipetted
into HPLC autosampler vials for LC-MS/MS analysis. QC standards (1.2, 7 and 40
ng/mL) were run with the dosed samples to confirm acceptable performance of the
method.

A series of dilutions were done (10-fold or 100-fold) with single blanks in order
to adjust the concentration of NGP1-01 in the mouse dosed serum, brain and retinal
samples to be within the linear range of the calibration standards.

4.4. LC-MS/MS analysis

The analysis was performed using an LC-MS-MS system in which a Shimandzu
UPLC system (Columbia, MD, USA) was interfaced to an AB Sciex QTrap 5500 mass
spectrometer equipped with an electrospray ionization (ESI) source (Framingham, MA,
USA). The UPLC system consisted of a Prominence DGU-20A3R inline degasser, two
LC-30AD pumps, a SIL-30AC autosampler, and a CBM-20A controller. Following the
sample preparation described above, 10 μL of each prepared sample (section 2.5) was
injected on to a Kinetex phenyl-hexyl column (100 x 2.1 mm, 2.6 μm) from Phenomenex
(Torrance, CA, USA). An optimized linear gradient of mobile phase of A, 5mM of
ammonium acetate in 2% ACN, and mobile phase B, 5mM of ammonium acetate in
100% ACN at 0.2 ml/min, was developed. The gradient program is given in Table 4.1.
The column was equilibrated for 10 minutes before each sample injection. The run time
for each injection was 12 min.
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Table 4.1. HPLC gradient program

Minutes

B%

0-3

45 (isocratic)

3-9

45-95

(linear)

9-12

95 (isocratic)
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Mass spectrometric analysis was positive electrospray ionization employing
multiple reaction monitoring (MRM) at the transitions of m/z 266 → 91 for NGP1-01 and
280 → 105 for IS. The optimized ionization MS parameters were as follows: ion spray
voltage (5000 V), declustering potential (60 V), entrance potential (8 V), collision energy
(40 V), collision exit potential (9 V), and nebulizer temperature (450 ⁰ C). Data
acquisition and processing were done using the Analyst software (version 1.6.1) from AB
Sciex.

4.5. Method validation

A complete bioanalytical method validation of NGP1-01 in mouse serum was
done

following

the

FDA

guidelines

for

industry

(www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf) and other reference [55].
The analytical method was validated for linearity, selectivity, precision and accuracy,
recovery, matrix effect and stability.

Calibration curves were established by plotting the peak area ratios of NGP1-01
to IS (y) versus the spiked NGP1-01 concentrations (x) of the calibration standards (n=2
for each calibrator). The slope and correlation coefficient of the calibration curve were
calculated using a weighted (1/x) linear regression.

Six double blanks were matched to six 0.5 ng/mL calibrator standards prepared
from six individual lots of mouse serum to determine any extent of interfering
chromatographic peaks and the signal response of the lowest calibrator.
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Precision and accuracy were assessed by analyzing the of 1.2, 7.0 and 40 ng/mL
QC standards. Intra–assay [within a day, n=5 for each QC standard (5 samples, each
individually prepared and analyzed according to sections 2.5 and 2.6, respectively)] and
inter-assay (five days, one of each of the QC standards prepared and analyzed each day,
for n=5 for each QC standard) precision was determined as % CV. Accuracy was
determined by comparing experimentally measured concentrations of NGP1-01 in QC
standards versus theoretical values.

The

absolute

extraction

experimentally determined

recovery was

determined

by comparing the

NGP1-01 peak areas of QC standards (1.2, 7.0 and 40

ng/mL), prepared and analyzed normally (NGP1-01 added prior to sample preparation),
with the NGP1-01 peak areas of QC standards prepared with NGP1-01 added after
sample preparation (n=3 for each pre- and post-addition QC standard).

The matrix effect study for mouse serum was assessed by comparing the peak
areas of NGP1-01 for QC standards (1.2, 7.0 and 40 ng/mL) with the peak areas of
NGP1-01 for similar concentrations of QC standards prepared in 80% ACN in water (n=3
for each QC and matched standard).

The stability of NGP1-01 in pooled serum was evaluated by preparing QC
standards at two different concentrations (1.2 and 40 ng/mL). The stability of NGP1-01
was tested for the following conditions: (1) short term stability at room temperature for 8
h (pre-preparation), (2) stability at room temperature for 10 h (post-preparation), (3) longterm stability stored at -20⁰ C for 60 days (pre-preparation), (4) freeze-thaw stability
through three freeze-thaw cycles for three consecutive days (pre-preparation). All
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experiments were run in triplicates for each QC concentration. These QC standards were
compared with the theoretical values.

The stock solution stabilities of NGP1-01 and IS were evaluated by comparing the
experimentally determined NGP1-01 concentrations of QC standards at 1.2 and 40
ng/mL (n=3) prepared from stored NGP1-01 stock solution (at -20 ⁰ C) for nine months
and freshly prepared NGP1-01 stock solutions.

4.5.1. Precision calculations for matrix factor and absolute recovery studies

The matrix factor and absolute recoveries were determined as a ratio of average
peak areas (see Table 4.3 and 4.4), in which the numerator and the denominator peak
areas are experimentally determined average peak areas, each having a standard
deviation.

4.6. Results and discussion

4.6.1. Mass spectra and liquid chromatography

It was observed that NGP1-01 and the IS produced protonated molecular ions
with strong intensity at m/z 266 and 280 respectively. As can be seen in their product ion
spectra (Figure 4.9), predominant daughter ions of m/z 90 and 105 were generated by
fragmentation of m/z 266 and 280, respectively. The MRM transitions of m/z 266 → 91
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for NGP1-01 and 280 → 105 for IS were chosen for quantification in this study (Figure
4.10).

Various isocratic schemes employing different concentrations of ACN or
methanol were investigated, but the peak shapes were irregular and the NGP1-01 and IS
peaks were not as well separated. Optimized resolution and good peak shapes for NGP101 and IS were achieved using mobile phases of 5 mM ammonium acetate in 2% ACN
(A) and 5 mM ammonium acetate in 100% ACN (B) employing a linear gradient (Table
4.1). Addition of ammonium acetate in the mobile phase not only enhanced the signals
but also improved the peak shapes for both the analyte and IS. Also, no carryover was
noted after a high concentration NGP1-01 run followed by a blank run.

Various gradient programs of methanol in 5 mM ammonium acetate were also
evaluated. However the chromatographic performance was not as good as that obtained
with the ACN gradient as given in Table 4.1.

139

Figure 4.9. The production ion spectra of NGP1-01(A) and the internal standard (B)
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Figure 4.10. The proposed fragmentation patterns of NGP1-01 (A) and the IS (B)
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4.6.2. Calibration plot and chromatographic interference assessment

A calibration plot of the peak area ratios of NGP1-01 to the IS (y) versus NGP101 concentration (x) employing linear regression using a weighting factor of 1/x yielded
y = 0.239x + 0.0185 with r = 0.9996, confirming linearity in the range of 0.5-50 ng/mL.
The lowest calibration standard of 0.5 ng/mL in the present work (accounting for a 5-fold
dilution resulting from the sample preparation in the present work) is three orders of
magnitude better than the limit of detection of the only published HPLC technique for
NGP1-01 [33]. Given that the signal/noise detector response for this 0.5 ng/mL calibrator
is high [see Figure 4.11B (1 and 2)] means that the actual detection limit and limit of
quantification is much lower for the present technique.

Chromatographic interfering peaks of this method was evaluated by comparative
analysis of the lowest calibration standard (0.5 ng/mL) matched with double blanks
prepared from six individual lots of mouse serum. As shown in Figure 4.11A (1 and 2),
there were no interfering peaks at the retention time windows of the analyte and the IS at
5.52 and 4.39 min, respectively. The precision (%CV) and accuracy (%RE) for the lowest
calibration standard were 5% and 1% respectively. A representative NGP1-01 dosed
serum sample diluted to 2.8 ng/mL is shown in Figure 4.11C (1 and 2).
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Figure 4.11. Representative MRM chromatograms of NGP1-01 (A1, B1, C1) and
phenyl-ethyl-NGP1-01(A2, B2, C2) for double blank (A1 and A2), 0.5ng/mL NGP101 calibration standard and 5ng/mL IS (B1 and B2), and a dosed mouse serum
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sample at 2.8ng/mL NGP1-01 and 5ng/mL IS (actual concentration after dilution)
mouse serum (C1 and C2).

4.6.3. Precision and accuracy

Intra- and inter-assay precisions and accuracies were evaluated by analyzing low,
mid and high QC standards for five replicates. As summarized in Table 4.2, the %RE for
intra- and inter-assays were in a range of -2.5% to 3.4%. The coefficients of variation
(%CV) for intra- and inter-assay were ≤ 4.3%. These values are within the acceptable
limits according to FDA guidelines.
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Table 4.2. Precision and accuracy of intra-assay and inter-assay for the
quantification of NGP1-01 in mouse serum (n=5)

Intra-Assay
Spiked
NGP1-01
conc.(ng/mL)
Low
Mid
High

1.2
7.0
40

Measured
NGP1-01
conc.(ng/mL)
Mean±SD
1.17±0.02
7.24±0.07
39.2±1.7

Precision Accuracy
%CVa
%REb

1.7
0.9
4.4

-2.4
3.4
-2.1

Inter-Assay
Spiked
NGP1-01
conc.(ng/mL)
Low
Mid
High

1.2
7.0
40

a

b

Measured
NGP1-01
conc.(ng/mL)
Mean±SD
1.172±0.013
7.054±0.094
40.32±0.697

Precision Accuracy
%CVa
%REb

1.11
1.33
1.73

-2.5
1.14
0.5

%CV = (Standard Deviation/Mean) x 100%

%RE = [(Measured – Spiked)/Spiked] x 100%
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4.6.4. Matrix effect and absolute recovery

The matrix effect was determined as a matrix factor (MF) by calculating the ratio
of peak areas from serum blanks (after processing) spiked with NGP1-01 at three QC
concentrations to the peak areas of NGP1-01 added to 80% ACN at the same
concentrations. The matrix factor (MF) for each concentration was calculated and given
in Table 4.3. Results yielded MF ratios of 1.01 – 1.02, indicating that there is no matrix
interference.

The absolute recoveries were determined for QC standards (1.2, 7.0, and 40
ng/mL) comparing peak areas for pre and post-preparation addition of NGP1-01 in
triplicate. As indicated in Table 4.4, excellent recoveries were obtained over three
concentrations for NGP1-01 in mouse serum matrix. The absolute recoveries were 99%102%, with a %CV ≤ 4.5%.
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Table 4.3.Absolute Matrix factor of NGP1-01 in mouse serum (n=3)

NGP101 conc.
(ng/mL)

Mean
matrix
factor

1.2
7.0
40

± SD
1.01±0.048
1.01±0.028
1.01±0.036

a

CV%a

4.7
2.8
3.6

CV% = (Standard Deviation/Mean) x 100%

%
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Table 4.4. Absolute recovery of NGP1-01 in mouse serum (n=3)

NGP1-

Mean

01 conc.

recovery

CV%a

(ng/mL)
± SD

a

1.2

101±4.4

4.3

7.0

99±0.50

0.5

40

101±0.92

0.9

CV% = (Standard Deviation/Mean) x 100%

%

148

4.6.5. Stability

The stability of NGP1-01 in mouse serum was determined under different storage
conditions by measuring the QC standards at two concentrations using the calibration
curves constructed from freshly prepared calibrators and comparing with theoretical
values. As summarized in Table 4.5, pre-preparation samples were found to be stable
(with a recoveries ranging from 97-101%): (1) stored at room temperature for 8 hours; (2)
stored at -20o C for 2 months; and (3) after 3 freeze-thaw cycles. Post-preparation NGP101 samples were also found to be stable after storing at room temperature for 10 hours
(97-102%). The stock solution stability of NGP1-01 after 9 months stored at -20oC was
determined to be 98% with a %CV of 5%. These results indicate that NGP1-01 was
stable for the experiments undertaken in the present work.
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Table 4.5. Stability studies of NGP1-01 in mouse serum pre- and post-preparation
(QC standards) (n=3)

Stored
sample

Spiked
NGP1-01
conc.
(ng/mL)

2 months at 200C
(Prepreparation)

Low
High

1.2
40

Measured
NGP1-01
conc.
(ng/mL)
Mean ± SD
1.17±0.04
40.9±0.70

3 Freeze thaw
cycles
(Prepreparation)

Low
High

1.2
40

1.16±0.01
40.3±0.37

97
101

10 hr at RT
(Postpreparation)
8 hr at RT
(Pre
preparation)

Low
High

1.2
40

1.16±0.05
40.6±0.20

97
102

Low
High

1.2
40

1.17±0.02
40.2±0.20

98
101

a

Stability
(%Recoverya)

98
102

%Recovery = Measured / Spiked x 100%
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4.6.6. Method applicability to pharmacokinetic studies

This validated LC-MS/MS assay has been successfully applied for the
determination of NGP1-01 in dosed serum, brain and retinal samples at a 1-hour time
point from four different mice. The mice were given a single dose of NGP1-01 at 20mg /
kg by intraperitonial administration. The results are given in Table 4.6. The results show
that NGP1-01 distributed into the blood as well as into the brain and retinal tissues. The
high concentrations of NGP1-01 in brain and retinal tissues at 1 hour time point indicate
a rapid distribution to these tissues from blood, readily passing the blood brain barrier in
mice. Representative chromatograms of NGP1-01 in dosed serum, dosed brain, and dosed
retina can be seen in Figure 4.11C (1 and 2) and Figure 4.12.
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Table 4.6. Measured concentration of NGP1-01 in dosed serum, brain and retina
samples at 1 hr time point

Amount
injected

Administration

Measured conc. (ng/mL)

Serum
20mg/kG

Mean ± SD (4mice, n=1)
Brain
Retinal

Intraperitoneal
19.5 ± 9.2
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44.0 ± 7.5

74.0 ± 41.7

.

Figure 4.12. Representative MRM chromatograms of NGP1-01 (A1 and B1) and
phenyl-ethyl-NGP1-01 (A2 and B2) for a dosed mouse brain sample at 11.3 ng/mL
NGP1-01 (actual concentration after dilution) (A1 and A2) and for a dosed mouse
retina sample at 9.2 ng/mL NGP1-01 (actual concentration after dilution) (B1 and
B2).
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4.7. Conclusion

A rapid and sensitive internal standard LC-MS/MS method has been developed and
validated for the quantitative measurement of NGP1-01 in mouse serum. A simple
protein precipitation sample preparation method was used. The method employed a
phenyl-hexyl reversed phase HPLC column for separation of the analyte and the internal
standard from matrix interference and a MRM mode detection for sensitive and selective
detection of the compounds. An ACN gradient with addition of ammonium acetate to the
mobile phase was found to give good chromatographic performance in terms of
resolution and peak shape. The assay gave a minimum linear calibration range of 0.5 - 50
ng/mL. The intra and inter-assay precision (%CV) and accuracy (%RE) of this method
are well within the FDA guideline limits. NGP1-01 in serum was found to be stable under
different storage conditions. This method has been applied to quantify NGP1-01 in
limited number of dosed mouse serum samples to show the suitability for undertaking
full NGP1-01 pharmacokinetic studies.
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CHAPTER 5

FUTURE RESEARCH PLAN

Gradient chromatofocusing has shown a great promise in the separation of protein and
multiple forms of protein isoforms in terms of resolution and peak widths by employing
generated smooth linear pH gradients on weak anion-exchange columns. But more
studies to be done to make gradient chromatofocusing more competent separation
technique in the field of protein characterization. The future research plans for GCF are
described as follows:

Generating smooth linear pH gradients by introducing bridging buffers between
application and elution buffers on different ion-exchange columns including strong
anion-exchange column, weak cation-exchange column as well as strong cation-exchange
columns. So far the pH range of generated pH gradients were 6.5 to 2.5 for weak anionexchange columns as discussed in previous chapters. This pH range can be extended from
12 to 2 and 2 to 12 for anion-exchange and cation-exchange columns respectively by
adding buffer components in application and elution buffers. This broad pH range of pH
gradient generation will enable to isolate more number of proteins. Then study the effect
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of number of buffer components on the separation of protein mixture employing
generated smooth linear pH gradients on different kind of ion-exchange columns. This
study will help us to find out what kind of columns are the best for gradient
chromatofocusing separation of protein samples.

Computer modeling of the generation of pH gradients in gradient chromatofocusing: In
gradient chromatofocusing, there are three different pH gradients include inlet, column,
and outlet pH gradients. If a computer model is developed for the gradient
chromatofocusing process, the above three pH gradients can be calculated by using this
model without doing any experiment. This will save a lot of time to generate these pH
gradients and enable to better understanding of the GCF process.

Integrating the gradient chromatofocusing with quadrupole-time-of flight mass
spectrometry to detect and molecular mass determination of multiple forms of prolactin
and lipoxygenase by carefully selecting some volatile buffer components which are
compatible with mass spectrometry. The few of the buffer components of buffer systems
discussed in previous chapters can be replaced with new buffer components which are
volatile to generate smooth linear pH gradients. The generated pH gradients can be
employed in GCF-MS pI based separation and detection of multiple forms of different
proteins. If this can be achieved, GCF will become more powerful technique for protein
analysis.
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Applying GCF-MS technique to analyze the biological samples: GCF-ESI-MS technique
has shown great promise in characterization of the standard protein samples. Since no
biological samples have been analyzed so far by this technique, more studies need to be
done to use this technique for separating and analyzing biological samples.
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